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ABSTRACT 
Background. Oropharyngeal squamous cell carcinoma (OSCC), where tonsillar 
(TSCC) and base of tongue squamous cell carcinoma (BOTSCC) dominate, is 
increasing and is now the most common head and neck squamous cell carcinoma 
(HNSCC) in Sweden. Smoking and alcohol are risk factors for HNSCC, but in 2007, 
human papillomavirus (HPV) infection was also recognized as a risk factor for OSCC. 
Notably, HPV positive OSCC has a much better clinical outcome than and HPV 
negative OSCC. The last decade treatment of HNSCC, including OSCC, has been 
intensified with chemoradiotherapy, due to the generally poor prognosis of HNSCC. 
Such treatment, with more side effects, is likely needless for most HPV positive OSCC, 
but since around 20% of the patients do not do well, additional markers are needed to 
single out patients with an expected favourable outcome before possible de-escalation 
of treatment. 
Aims. To follow incidence and HPV prevalence in OSCC over time in order to 
understand why OSCC has increased. To search for additional predictive biomarkers in 
HPV positive OSCC, to more safely de-escalate treatment. 
Results: In papers I-II we showed that the prevalence of HPV in TSCC had increased 
significantly in Stockholm from 23% (1970-1979); to 28% 1980-1989; to 57% 1990-
1999; to 79% 2000-2007. Notably, also during the 2000s there was a significant 
increase in HPV prevalence, from 68% 2000-2002; to 77% 2003-2005; up to 93% 
2006-2007. Likewise, HPV prevalence also increased in BOTSCC, from 58% 1998-
2001 to 84% 2006-2007. The increase in HPV prevalence was paralleled by an increase 
in incidence of TSCC and BOTSCC, and when estimating the HPV incidence in TSCC, 
the incidence had increased 7-fold from 1970 to 2006. In paper III we found that HPV 
positive TSCC had significantly more CD8+ and Foxp3+ tumour infiltrating 
lymphocytes (TILs), and that a high CD8+TIL count was correlated with a favourable 
clinical outcome in both HPV positive and negative TSCC. In addition, a high CD8+ 
count and a high CD8+/Foxp3+ ratio were significantly correlated with a favourable 3-
year disease-free survival in HPV positive and negative TSCC respectively. In papers 
IV-V, we show that absence of “classical” HLA class I intensity staining was correlated 
with a favourable disease-free survival, disease-specific survival, overall survival and 
progression-free survival in patients with HPV positive OSCC, and to a worse clinical 
outcome in patients with HPV negative OSCC. Moreover in paper V, patients with 
HPV positive OSCC with absence of /or weak “classical” HLA class I intensity 
staining presented a very high survival that was independent of treatment regime. HLA-
E, -G was also analysed in TSCC, but without any outcome correlation. In addition, 
HLA class II expression was analysed and found to be more common in HPV positive 
than HPV negative OSCC, but correlated to better clinical outcome only in the latter 
group.  
Conclusion: A parallel increase in incidence as well as HPV prevalence in TSCC and 
BOTSCC was demonstrated suggesting HPV infection being responsible for the 
epidemic increase in OSCC. Finally, HPV positive TSCC or OSCC with high CD8+ 
TIL counts or with absent/weak HLA class I intensity staining presented a very good 
clinical outcome, suggesting that these markers could potentially be used to select 
patients for prospective randomised trials de-escalating oncological treatment. 
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1 INTRODUCTION 
	  
Although there are reports from, as early as, 1876 describing transmission of tumours 
from one animal to another, the field of tumour virology is considered to start with 
Peyton Rous famous chicken experiments in 1909 (Figure 1). In these experiments, 
Rous was able to grind and filtrate a tumour, a sarcoma, from a chicken on a very fine 
pore filter, where no cells were able to pass, and then inject the filtrate into another 
healthy chicken. Some time later, Rous observed the injected healthy chicken 
developed a sarcoma. He then repeated the procedure and injected the filtrate from the 
newly “contaminated” chicken into another healthy chicken, and again this originally 
healthy chicken developed a tumour. The filtrate, that did not contain any cells, was 
later demonstrated to contain a virus, which sooner was named as Rous sarcoma virus 
(RSV), and the idea that cancer was just another example of an infectious disease was 
born.(Weinberg 2007; Moore et al. 2010)  
 
The tumour virology field expanded in the beginning of the 20th-century, and in 1913 
Fibiger reported that stomach cancer in rats was associated to bacterial agents, 
supporting the idea that cancer was an infectious disease. However, a few years later, 
Fibiger’s work was dismissed – the rats did not get cancer, just metaplasia due to 
vitamin deficiencies – and the focus on the origin of cancer was shifted again, the 
researchers started to focus on chemicals as inducers of cancer instead.(Weinberg 2007; 
Moore et al. 2010) 
	  
	  
	  
	  
	  
Nobel&Prize&in&1965&&
Figure 1. Experimental setup of Rous famous chicken experiment and the discovery of Rous 
sarcoma virus. The myth tells that a caring chicken farmer, living on Long Island, came up one 
morning to Dr. Rous with one of his chickens that newly had developed a tumour. However, instead 
of examining the chicken, Dr. Rous chopped the chicken’s head off, extracted the tumour, filtrated it 
and injected it into another healthy chicken, which also developed a tumour. Rous then repeated the 
experiment serially and showed that the tumour-causing agent (later identified as Rous sarcoma virus) 
could be propagated. In 1965 he was awarded the Nobel Prize in Medicine for this discovery; whether 
the farmer was economically compensated for the chicken is still, though, shrouded in mystery. 
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After the initial detection of Rous sarcoma virus and all attention on tumour viruses, 
there came a time when the days of glory seemed to have passed for tumour virologists, 
but the research continued, and eventually more tumour viruses were discovered over 
the years. The first mammalian tumour virus to be detected was murine polyomavirus 
and this led to a revival in the interest of tumour viruses especially in mammals and of 
course especially in humans.(Moore et al. 2010) 
 
Today, there are at least 7 discovered oncogenic viruses (belonging to 6 families) in 
man, and more viruses are to be expected as a consequence of new bio-molecular 
methods.(Moore et al. 2010) In this context, the detection of the association of human 
papillomavirus (HPV) and cervical cancer is a very famous example, where Professor 
Harald zur Hausen was awarded the Nobel Prize in Medicine in 2008 (Table 1). 
 
Table 1. Tumour viruses in man and their association with malignancies presented in chronological 
order. Data obtained from (Moore et al. 2010). 
      
The means of how human viruses cause tumours differs between viruses, but three 
main mechanisms can be distinguished and they are:   
 
- The integration of the viral genome into the host genome 
- The interaction of viral proteins with the host protein machinery  
- Chronic inflammation 
 
In the case of HPV, the virus of importance in this thesis, the published literature has 
focused on the second mechanism, and as we will see in the following chapters, this is 
the most important mechanism used by HPV to transform human cells.  
 
Moreover, the focus of this thesis is on HPV and its role in oropharyngeal cancer. 
Therefore, we will now leave tumour virology as such, and a brief introduction to (1) 
HPV and (2) oropharyngeal cancer will be presented. 
Virus& Family& Associated&
malignancies&
Year&descirbed&
Epstein8Barr&virus&(EBV)& Herpesviridae* Burki.’s*lymphoma,*
nasopharyngeal*carcinoma,*
some*Hodgekin’s*disease,*
some*non9Hodgekins*disease*
and*some*gastrointes;nal*
lymphomas*
1964*
Hepa>>s&B&virus&(HBV)& Hepadnaviridae* Hepatocellular*carcinoma* 1965*
Human&T8lymphotropic&virus&I&
(HTLV8I)&
Retroviridae* Adult*T*cell*leukaemia* 1980*
High&risk&human&
papillomavirus&16&(HPV816)&
Papillomaviridae* Cervical,*anal,*penile,*vulvar*
and*head*and*neck*cancer*
1983*
Hepa>>s&C&virus&(HCV)& Flaviviridae* Some*hepatocellular*
carcinomas*and*some*
lymphomas*
1989*
Kaposi’s&sarcoma&herpesvirus&
(KSHV&or&HHV8)&
Herpesviridae* Kaposi's*sarcoma* 1994*
Merkel&cell&polyomavirus&
(MCV)&
Polyomaviridae* Merkel*cell*carcinoma* 2008*
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1.1 HUMAN PAPILLOMAVIRUS (HPV) 
Viruses belonging to the family of Papillomaviridae are a group of small, non-
enveloped viruses infecting mammals mainly asymptomatically, but also causing 
benign tumours/warts, and in some cases also neoplasias. In humans, so far over 150 
different human papillomavirus (HPV) types have been identified and 12-18 of these 
are considered to be oncogenic.(IARC-Monographs 2009)  
 
 
 
1.1.1 History 
How the field of HPV in cervical, as well as head and neck cancer and other diseases 
emerged during the last century is beautifully described in a review by zur Hausen in 
Virology from 2009.(zur Hausen 2009) Here only a brief summary will be presented.  
 
A high frequency of cervical cancer among prostitutes, but a very low in nuns and 
virgins, was noticed centuries ago, and was first reported in women followed during 
1760–1839 in Verona Italy. As a consequence, during the 20th century, in parallel with 
the development of bacteriology/virology, many researchers tried to establish a link 
between cervical cancer and a sexually transmitted agent. Initially, attempts were made 
to link herpes simplex virus type 2, to the disease; but during the 1970´s HPV entered 
the scene. The first experiments that tried to establish a link between HPV and cervical 
cancer were initiated in 1972, but it was not until 1982 the first HPV type 16 sequences 
in cervical cancer were published. In 1983 HPV-16 DNA was isolated by southern blot 
from cervical cancer tissues, by the zur Hausen group.(zur Hausen 2009) 
 
The rest is history, and today HPV is considered as a carcinogenic infectious agent, not 
only in cervical cancer, but also in some anal, penile, vulvar and head and neck cancers 
(discussed in 1.1.9). 
	  
	  
	  
1.1.2 Genome structure and viral particle 
The Papillomaviridiae family consists of small (55nm in diameter), non-enveloped, 
double-stranded circular DNA viruses (Figure 2). The genome (∼8000 base pair) can be 
divided into three major regions; the early region (E) that covers about 50% of the 
genome; the late region (L) that covers about 40% and the non-coding region (NCR) 
that covers approximately 10% of the genome (Figure 2). The early region contains the 
early open reading frames (ORF; ∼genes) and encodes the early regulatory proteins E1, 
E2, E4, E5, E6 and E7 – and in HPV-31 also E8), while the late region encodes the late 
proteins L1 and L2, which together account for the viral capsid. Two poly-adenaylation 
(pA) sites separate the three regions, the early (pAE) and the late (pAL). The genome of 
HPV-16 is suggested to contain two major promoters, the early p97 and the late p670. 
The first is located upstream of E6 and is involved in the transcription of the early 
genes, while the latter is located within the E7 ORF and is responsible for the late 
transcripts.(Doorbar 2006; Zheng et al. 2006)  
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1.1.3 Classification 
As described above, all HPVs share a common genetic structure and some genetic parts 
are more conserved than other parts. One such well-conserved part, that is present in all 
papillomaviruses, is the L1 region, which is the framework in the papillomavirus 
classification.(de Villiers et al. 2004; Bernard et al. 2010) 
 
The classification system is built up as a phylogenetic tree, in which the “family” is the 
root. Viruses belonging to the papillomavirus family, the Papillomaviridae, share the 
same structure and organisation, but the genetic sequence may diverge more than 55%. 
The family is divided into genera (alpha-pi), with 40-50% diversity to other genera; 
five of these genera (alpha, beta, gamma, Nu and Mu) are infectious in man – i.e. HPV.  
Branches within the genus are called “species”. The species are divided into “types”, 
and types within one species resemble each other more than 90% in their L1 region. 
Further separation may, in some cases, include sub-types (2-10% difference in L1) and 
variants (less than 2% diversity in L1). The most prevalent HPV type in head and neck 
and cervical cancer is HPV type 16 (HPV-16), which belongs to species 9 and the 
alpha-genus.(de Villiers et al. 2004; Bernard et al. 2010) Moreover, although there is 
scientific focus on the oncological potential of different HPV types, there are also data 
suggesting that intra-type variants (e.g. variants of E6 ORF) for HPV-16 may differ in 
oncogenic potential in cervical cancer.(Huertas-Salgado et al. 2011) 
 
Another characteristic the HPV family is the division into cutaneous or mucosal HPVs, 
depending on which tissue the specific HPV type infects. Cutaneous HPVs have mainly 
been isolated from epithelial surfaces, e.g. from plantar warts (e.g. HPV-1) or patients 
with verruciform epidermodysplasia (e.g. HPV-8); while mucosal HPVs have been 
isolated from mucosal surfaces, e.g. laryngeal papillomas (e.g. HPV-6) and cervical 
cancer (e.g. HPV-16).(IARC-Monographs 2009) Another characterisation of HPV 
includes the separation into high-risk and low-risk types in cervical cancer. High-risk 
HPVs (e.g. HPV 16, 18, 31, 33, 35,) are more often associated with malignant tumours, 
while low-risk HPVs (e.g. HPV 6, 11, 34) are more seldom associated with neoplasias. 
There are also putative high-risk types, e.g. HPV 26, 53 and 66.(Munoz et al. 2003; 
IARC-Monographs 2009)  
Figure 2. A proto-form of (A) the HPV genome (B) the icosahedral shaped viral capsid 
A	  
 
B	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1.1.4 Transmission  
HPV is mainly transmitted by skin-to-skin or mucosa-to-mucosa contact. In cervical 
infections, HPV is primarily sexually transmitted, and the risk of being HPV infected is 
correlated to the numbers of sexual partners, young age and early sexual debut.(Winer 
et al. 2003; Lenselink et al. 2008; Ramqvist et al. 2011b; Plummer et al. 2012) In 
oral/oropharyngeal infections, the route of transmission is still not fully elucidated. 
Although sexual contact (oral-to-genital) has been suggested as an important 
transmission route, other pathways, e.g. mother-to-child (at birth) and mouth-to-mouth 
(sometimes referred to as “kissing”), have been proposed.(D'Souza et al. 2009)  
 
Nevertheless, how HPV infection is established, i.e. in which way the virus gains 
access to the basal layer is not fully understood. It has however been suggested that 
heparin sulphate proteoglycans and α-6 integrin may be of importance for binding of 
the virus to cells. Nonetheless, uptake of the virus after binding to human cells is slow, 
and upon endocytosis, facilitated by the viral E2 protein, viral DNA is transported to 
the nucleus.(Sapp et al. 2009; Schiller et al. 2010) In the nuclei, the viral genome is, 
usually, maintained as an episome.(Doorbar 2006) 
 
Another issue that is not completely unravelled is whether the virus has a very specific 
tissue tropism. It has for a long time been accepted that some HPV types preferentially 
infect the epithelial cells within the transformation zone of the cervix, where the 
squamous epithelium turns into columnar epithelium. It has therefore been proposed 
that HPV has an affinity for “squamocolumnar junctions”.(Moscicki et al. 2006) 
Likewise, in e.g. tonsillar cancer (discussed in 1.2.1), the corresponding site to the 
cervical transition site is suggested to be the crypts.(Kim et al. 2007) However, it is 
noteworthy to comment that there are no squamocolumnar junctions in the tonsils. 
 
 
 
1.1.5 Viral life cycle  
During most infections with HPV, its gene products are highly regulated in means of 
levels, and time for expression, and HPV does not usually cause malignant tumours. A 
productive HPV infection can be separated into different stages, in which different viral 
proteins play specific roles and are more abundant than during other stages (Figure 3).  
 
The viral life cycle starts at the basal membrane upon infection and with the viral 
genome being episomal. It has been suggested that the viral genome is replicated during 
the cellular S-phase and that the numbers of viral copies/cell are stable with around 10-
200 copies/cell.(Doorbar 2006)  
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Figure 3. Viral life cycle. Viral protein and DNA expression in the different epithelial layers.(Doorbar 
2006)  
 
 
As mentioned above, transcription of viral proteins is initiated by the early promoter, 
p97 in HPV-16 (Figure 3 and 4). Transcription, both from the early and the late 
promoter, occurs from only one of the two viral strands and both generate long pre-
mRNA strands, that later are spliced into viral mRNA, as illustrated in Figure 4.(Zheng 
et al. 2006) 
 
Viral proteins E1 and E2 are the two most important viral proteins during early 
infection. E2 plays many crucial roles, e.g. it binds viral DNA in the NCR and recruits 
E1, which in turn recruits the cellular proteins necessary for DNA replication, e.g. α 
DNA polymerase.(Doorbar 2006) In addition, E1 also exhibits a helicase function, 
opening the viral DNA for cellular replication proteins, by binding to A/T rich regions 
in the NCR. E1 is therefore regarded as essential for initiation of viral replication. 
(Wilson et al. 2002) Upon cellular replication, following S-phase, E2 is suggested to 
play another important role, in that it anchors the viral episomes to mitotic 
chromosomes and allows the viral genomes to split equally. 
 
E2 also plays an important role in regulating viral transcription. Low levels of E2 
activate early transcription, while abundance of E2 inhibits early promoter transcription 
and it has been proposed that E2 can repress the TATA box binding protein (important 
for initiation of transcription).(Doorbar 2006; Zheng et al. 2006; Thierry 2009) As 
stated previously, the early promoter initiates transcription of E1 and E2 as well as E4-
E7. It is also the only mediator for transcription of E6 and E7, which together are 
important for abrogating normal cell cycle control and pushing the cells to proliferate, 
and E6 and E7 will be discussed more extensively below with regard to transformation 
(section 1.1.7). Similar to E2, transcription of E4 and E5 by the early promoter is less 
efficient as compared to that initiated by the late promoter, as described below (Figure 
3 and 4)(Moody et al. 2009).  
 
 
  7 
 
Figure 4. A schematic model of the HPV genome and its transcripts, presented here for HPV-16. 
The full genome (∼8 kb) is presented with all the ORFs, the two promoters (p97 and p670), the two 
polyadenylation sites (for the early and late transcripts respectively) and the NCR (here presented as 
LCR). Moreover, the early and late transcripts are also presented below the viral genome. As indicated on 
the side, the possible splice-products are also presented.(Zheng et al. 2006) 
	  
 
 
Upon epithelial differentiation, transcription from the late promoter increases – which 
leads to high levels of E1, E1^E4, E5, L1 and L2 (Figure 3). The activity from the early 
promoter remains stable, giving low levels of E6 and E7 at all epithelial stages. 
Transcription of E1 and E2 changes also upon differentiation, and occurs not only from 
the early, but also from the late promoter. Moreover, in contrast to transcription from 
the early promoter, E2 levels do not down regulate transcription from the late promoter. 
As a consequence, the switch in promoter leads to higher transcription and replication, 
which gives a dramatic increase in viral copy numbers per cell.(Moody et al. 2009) 
However, which mechanisms that induce the promoter switch are still unrevealed.  
 
During the viral life cycle, E4 is the most abundant protein. It is accumulated in the 
cytoplasm, and its expression is increased upon cellular differentiation.(Doorbar 2006) 
However, the role of E4 is still enigmatic, but some studies claim a role of E4 in viral 
replication, transcription of the viral capsid proteins, and the release in viral particles. 
(Wang et al. 2004; Nakahara et al. 2005; Wilson et al. 2007) 
 
As mentioned above, another early protein that is transcribed more frequently from the 
late promoter is the E5 protein (Figure 3 and 4). This protein is small and hydrophobic 
 
 
  8 
and is, therefore, preferably detected in the Golgi and the endoplasmatic 
reticulum.(Moody et al. 2010) Moreover, in vitro studies have demonstrated a link 
between E5 and epidermal growth factor receptor (EGFR), in that E5 may increase 
EGFR levels as well as modulate EGFR signalling pathways. It has therefore been 
suggested that E5 has the ability to exhibit a weak transforming activity.(Moody et al. 
2009; Moody et al. 2010) Nevertheless, it should be noted that E5 is frequently deleted 
in cervical cancer (Tsai et al. 2003; Hafner et al. 2008) – suggesting that E5 is not 
necessary for cellular transformation. Another function of E5, and of interest for this 
thesis, is the ability of E5 to down-regulate human leukocyte antigen (HLA) class I 
expression (discussed in section 1.1.10.3.2). There are studies that suggest that E5 can 
accumulate HLA class I molecules in the Golgi apparatus; thereby reducing HLA class 
I expression and preventing the cells from cytotoxic T-cell clearance (for more details 
see section 1.1.10.3.2). In addition, a study by Zhang et al has also demonstrated that 
E5 is able to down-regulate HLA class II expression in interferon gamma (INF-γ) 
treated keratinocytes.(Zhang et al. 2003) Altogether, these studies suggest, that E5 may 
be able to decrease the immune recognition of HPV infected epithelial cells. 
 
The last step in the viral life cycle is virus assembly and release. The newly synthesised 
viral genomes are packed into icosahedral capsids, formed by the viral L1 and L2 
proteins. The capsid consists of 360 copies of the L1 protein and theoretically up to 72 
copies of the L2 protein.(Sapp et al. 2009) As mentioned above, the L1 protein self-
assembles (also discussed in section 1.1.11.1) and forms pentamers (capsomeres), and 
each viral capsid consists of 72 capsomeres. The L1 pentamers are formed in the 
cytoplasm and the virus particle in the nucleus. After packing, the virus particles are 
shed from the surface of the epithelium.(Doorbar 2006)  
 
 
 
1.1.6 HPV induced carcinogenesis 
As described above, E6 and E7 are expressed during the whole life cycle, but are more 
prominently expressed during the earlier stages of the viral cycle. E6 and E7 interact 
with the human cell cycle and drive it into S-phase, which enables the viral genome to 
replicate. A very simplified explanation of the abilities of E6 and E7 to induce S-phase 
is that E7 inhibits the Rb (retinoblastoma) protein, and E6 degrades the human p53 
protein (Figure 5).(Leemans et al. 2011)  
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Figure 5. A schematic overview of cell cycle deregulation by HPV. For details, please see the text in 
section 1.1.6 (Leemans et al. 2011) 
 
 
Normally, S-phase is induced by cyklins and cyklin-dependent kinases (CDK) upon 
mitotic signals. Upon such stimulation, the cyklin-CDK complexes phosphorylate the 
Rb protein (pRb), and inhibit its E2F binding. E2F transcription factors are then 
released and activated, and can e.g. induce S-phase genes. In an HPV infected cell 
however, pRb is inactivated by E7, and thereby S-phase is induced.(Doorbar 2006)  
 
The natural inhibitor of the CDK4/CDK6-CyklinD complex, that promotes S-phase, is 
the p16INK4a protein (belonging to the INK4 family, one of two CDK inhibitor families 
in mammals).(Canepa et al. 2007) In an HPV infected cell, p16INK4a is often up-
regulated (discussed in 1.2.7), which seems to some extent logic when studying figure 
5. However, in a recent study by McLaughlin-Drubin and colleagues, the authors 
showed that up-regulation of p16INK4a in HPV positive cells was due to KDM6B, a 
histone demetylase induced by HPV-16 E7. For this reason, it was therefore suggested 
that E7 mediated p16INK4a expression is independent of pRb inactivation.(McLaughlin-
Drubin et al. 2011)  
 
Moreover, in a well functioning cell, inhibition of pRb and deregulation of E2F would 
cause p53 activation e.g. by another CDK inhibitor in the INK4a family, CDKN2AARF 
(p14ARF). Activated p53 should then normally lead to halted cell cycle and to apoptosis. 
(Polager et al. 2009) However, cell cycle halting and apoptosis are inhibited, by the fact 
that E6 binds to and degrades p53 (Figure 5).(Doorbar 2006)  
 
During natural HPV infection, the levels of the oncogenic viral proteins E6 and E7 are 
low and are regulated by E2 levels (described in 1.1.5). However, in many tumours, the 
HPV genome may integrate into the human genome, causing a disruption in the E2 
ORF. Such disruption can lead to loss of E2 and allowing higher E6 and E7 levels, due 
to loss of their regulation by E2.(zur Hausen 2000; Munger et al. 2004) 
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The above-sketched overview is, indeed, a simplification of the interactions between 
the viral oncogenic proteins and the cellular machinery. It is also important to bare in 
mind, especially in head and neck cancer, that additional transforming processes/factors 
may co-exist at the same time, e.g. HPV infection and smoking.(Gunnell et al. 2006) 
Below the E6 and E7 and their interactions with cellular proteins will be described in 
more detail as well as the role of viral integration.  
 
 
1.1.6.1 E6 
 
E6 is a well-conserved oncogene, and the protein consists of 151 amino acids. 
Although one of the most studied functions of high-risk HPV E6 is the binding - in 
complex with the E6 associated protein (E6AP) – to p53, which thereby becomes 
ubiquitinated and degraded, other functions of E6 have also been identified.(Munger et 
al. 2004) One other such function is the ability of high-risk HPV E6 to bind the PDZ-
family protein. Such interaction may result in a degradation of the PDZ-domain 
resulting in deregulation of organization and differentiation and of the chromosomal 
integrity.(Feller et al. 2010) Other important functions include the ability of E6 to 
induce telomerase activity and mediate the degradation of pro-apoptotic proteins, e.g. 
Bak.(zur Hausen 2000) 
 
As stated above, much research has been directed on understanding the link between 
high-risk HPV E6 and p53. Studies on low-risk HPV have also shown the ability of E6 
to interact with p53, but without changing the turnover of p53.(Klingelhutz et al. 2012) 
Why this is the case has not been fully elucidated. However, it has been shown that 
high-risk HPV E6 can potentially bind to p53 at two locations, while low-risk HPV E6 
binds only to one location, suggesting different interactions between E6 of high and 
low-risk HPV types and p53.(Ganguly et al. 2009) 
 
The reason why high-risk HPVs are more oncogenic in some patients than others, have 
also gained a lot of interest the last years. Interestingly, a Nature paper some years ago 
(1998) investigating the role of polymorphism in p53, suggested that the E6 of HPV-16 
and HPV-18 would be more prone to degrade p53 with Arg rather than Pro at codon 
72. The authors also found that Arg p53 was more common among cervical cancer 
patients, compared to healthy controls.(Storey et al. 1998) However, other studies 
followed immediately and were not been able to support these findings.(Helland et al. 
1998; Hildesheim et al. 1998; Josefsson et al. 1998) 
 
E6 may also have an immune modulating capacity and this will be discussed below in 
section 1.1.10. 
 
 
1.1.6.2 E7. 
 
E7 is a 98 amino acid long protein with a plethora of functions. As already described 
above, one of its most important functions is to bind and destabilize pRb and the related 
tumour suppressors p107 and p130; which all three regulate the E2F family. 
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Furthermore, studies have shown that E7 of high-risk HPVs binds pRb with a 10 times 
higher affinity than E7 of low-risk HPVs, and this difference has been explained by a 
difference in one single amino acid.(McLaughlin-Drubin et al. 2009)  
 
E7 also has the ability to inhibit CDK inhibitors e.g. p21 and p27 (Figure 5). In 
addition, it has been suggested that E7 has the ability to enhance integration of foreign 
DNA, resulting in an increased mutagenesis, although the mechanism for this is not 
fully understood. In addition, E7 of high-risk HPVs has the ability to induce 
chromosomal instability, as also shown for E6.(McLaughlin-Drubin et al. 2009) 
Finally, E7 has also an immune modulating capacity and this will be discussed in more 
detail below in section 1.1.10. 
 
 
1.1.6.3 Viral integration.  
 
In the normal viral life cycle, the virus is maintained and replicates as an episome. 
However, in high-grade lesions and in cervical neoplasias the viral genome frequently 
integrates into the human genome.(Moody et al. 2010) It has been concluded that 
integration is not regulated (e.g. by integrases, as in HIV) and occurs most likely 
randomly in the whole human genome, possibly with a preference for fragile sites and 
most likely a consequence of chromosomal instability.(Thorland et al. 2000; Thorland 
et al. 2003) Irrespective of the mechanism behind it, integration of the viral genome has 
been suggested as an important step for, but not a pre-requisite for the development of 
invasive cervical cancer.(Pett et al. 2007; IARC-Monographs 2009) Explanations for 
this statement have in the literature been two: 
 -­‐ Upon integration viral DNA sequences may be deleted. Although different 
sequences may be lost, E2 is often deleted – leading to deregulated E6 and 
E7.(Woodman et al. 2007; Collins et al. 2009)  
 -­‐ Expression of important regulatory cellular genes may be affected by insertion 
of viral DNA.(Ferber et al. 2003; Ragin et al. 2007a) 
 
In cervical cancer, the published literature is consistent and today it is widely accepted 
that HPV genome integration occurs in ∼90% of the cases.(Pett et al. 2007) 
Nevertheless, in head and neck cancer the data are still insufficient and although many 
studies have claimed that the genome is integrated, the methods used are often indirect 
and inadequate. Many studies have quantified E2 and E6 DNA and in cases where E6 
dominates over E2, one has concluded the viral DNA to be integrated.(Venuti et al. 
2000; Koskinen et al. 2003; Kim et al. 2007) However, since integration is a likely 
random event and any HPV sequence may be lost in the process, it should, be 
impossible to adequately assess the integration status of the viral genome just by gene 
quantification. Moreover, the ratio between E2 and E6 has often also been used to 
quantify the degree of integration in these studies described above. Reasoning this way, 
a ratio of e.g. 0.5 implies that 50% of the viral genomes are integrated and 50% are 
episomal. However, E2 expression from an episomal HPV genome should theoretically 
be able to repress both integrated and episomal E6 and E7 expression.  
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Nevertheless, a study by Mellin et al, using a more appropriate method (detecting 
human-viral junctions) showed HPV to be only episomal and more importantly some of 
the episomes had deletions. On the other hand, this study was small (11 tumours) and in 
some of these tumours there were a very high viral load.(Mellin et al. 2002) Obviously, 
the role of viral integration in the head and neck region needs more investigation. 
 
 
 
1.1.7 HPV detection methods 
Many different detection methods for HPV have been described, and which method 
that is used in a study or a clinical setting is often dependent on what kind of 
material/tissue that has to be analysed. However, there are also cases where different 
methods may be feasible, and in these cases there is often a scientific debate about the 
optimal method. In general, four main methodology categories can be distinguished 2 
direct and two indirect): (1) direct detection of viral DNA/RNA in the tumour (2) direct 
detection of viral proteins in the tumour; (3) detection of serum antibodies (indirect 
detection method); and (4) detection of proteins that are up/down-regulated upon HPV 
infection (indirect detection method). Moreover, tumour material may also differ in that 
it can be fresh/fresh frozen or paraffin embedded. Below, a few examples of HPV 
detection methods are presented.  
 
(1) Detection of viral DNA/RNA. Different types of polymerase chain reactions 
(PCRs) have been used to define a tumour as HPV positive.(Venuti et al. 
2012) One of the most common methods used is a PCR with general (or 
consensus) primers and thereafter a system to visualize the products. General 
primers refer to that these primers can detect many different HPV types by 
binding to highly conserved regions within the viral genome.(Karlsen et al. 
1996) Examples of such primer-pairs are the GP5/GP6 (bind to L1 
region)(van den Brule et al. 1990); Gp5+/GP6+ (extended GP5/GP6 primers 
with 3nt – also binds the L1 region)(de Roda Husman et al. 1995); 
CPI/CDIIG (binds to the E1 region)(Tieben et al. 1993); MY09/MY11 (bind 
to the L1 region)(Karlsen et al. 1996) and SPF primer pairs (connect to the L1 
region)(Kleter et al. 1998). Although these primer pairs bind conserved 
regions, there is still a considerable mismatch, which also varies between 
HPV types.(de Roda Husman et al. 1995) Therefore, some HPV types are 
more easily detectable than others.(Schmitt et al. 2008) To overcome this 
problem, the PCR program is, most often, designed with a lower annealing 
temperature – allowing the primers to bind with mismatches. However, a 
lower annealing temperature cannot totally solve the mismatch problem, and 
therefore a new consensus primer multiplex setup, the broad-spectrum 
GP5+/6+, has recently been proposed. In this multiplex PCR setup, the 
authors reported an increased sensitivity for at least 10 HPV types.(Schmitt et 
al. 2008) After DNA amplification, some researchers have used probe-based 
techniques to type the PCR product (e.g. commercially available Luminex or 
InnoLiPa), while others visualize the product on a gel and thereafter use HPV 
type specific PCRs or sequencing.(Mellin et al. 2002; Ramqvist et al. 2011b) 
 
Another method, commonly used, is the in situ hybridization method. Here, a 
biotinylated probe is hybridised to the viral DNA and thereafter the signal, 
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and not the viral DNA as in the examples above, is amplified. The presence 
of, as well as the localisation of the viral DNA is then evaluated under a light 
microscope.(Venuti et al. 2012)  
 
Other DNA/RNA methods described may include detection of viral E6 and E7 
RNA, followed by cDNA synthesis that is followed by amplification and 
detection.(Venuti et al. 2012) There are also some very rare studies, where the 
presence of HPV DNA has been analysed for in serum from patients with e.g. 
head and neck cancer; but such detection methods should not be considered as 
sufficiently reliable.(Capone et al. 2000) 
 
 
(2) Detection of viral proteins in the tumour. Many different antibodies against 
the viral oncoproteins E6 and E7 have been developed over the years, but due 
to low sensitivity and specificity these antibodies have never been of any 
value in clinical samples. 
 
(3) Detection of serum antibodies. Methods detecting antibodies in sera against 
viral capsid proteins L1 and L2 as well as viral oncoproteins E6 and E7 have 
been used in e.g. epidemiological studies.(Mork et al. 2001; Poynten et al. 
2012) However, these antibodies are never site-specific and could also be a 
result of an earlier infection.  
 
(4) Detection of the p16INK4a protein, which is up-regulated upon HPV infection. 
Although there are many human proteins that are up/down-regulated upon 
HPV infection, overexpression of p16INK4a has by far most frequently been 
used to define HPV positive status in head and neck cancer. As described 
above, p16INK4a is up regulated as a result of degradation of pRb, caused by 
the viral protein E7.(Venuti et al. 2012) The advantages/disadvantages of 
using this marker in head and neck cancer will be discussed in section 1.2.7. 
 
So far, the most common methods used in the head and neck cancer field are the use of 
PCR with GP5+/6+ primers, in situ hybridisation and the p16INK4a expression analyses. 
Although different algorithms for HPV detection have been proposed (discussed in 
section 1.2.7) the optimal HPV detection method/algorithm is still under 
debate.(Smeets et al. 2007)  
	  
	  
	  
1.1.8 HPV prevalence in healthy populations  
HPV is one of the most common sexually transmitted diseases worldwide, and most 
sexually active individuals will be infected with HPV at some time point. Nevertheless, 
for the vast majority of infected individuals, HPV infection will pass asymptomatically 
and clear within 1-2 years.(Tota et al. 2011)  
 
When analysing the prevalence of HPV infection in healthy individuals, the rates vary 
widely between infection site and study populations. An attempt to summarise the HPV 
prevalence in healthy women was recently made in a meta-analysis by Bruni et al. In 
this analysis the authors reviewed all published data from studies between 1995 and 
  14 
2009 that included woman with normal cytology. The authors found a HPV prevalence 
of 7.2% worldwide (11.7% adjusted); but the prevalence differed immensely – from 1.6 
to 41.9%. Geographically, the prevalence also varied, from around 30% in Eastern 
Africa, the Caribbean and Eastern Europe, while it was lower in Northern America, 
Western Europe and Asia.(Bruni et al. 2010) Another similar meta-analysis published 
in 2005, but during a different timespan, came to a similar conclusion.(de Sanjose et al. 
2007) There also seems to be an age-specific distribution of HPV infection in females, 
with a first peak in women <25 years and a second in middle-aged women. (Franceschi 
et al. 2006; de Sanjose et al. 2007; Smith et al. 2008; Bruni et al. 2010) 
 
Genital HPV infection in sexually active men is also very common, and varies also 
greatly between countries and populations, and can depend on the sampling and testing 
methods used as well as the anatomical site that is investigated (scrotum, shaft, glans 
and urethra). In addition, it has been suggested that male genital HPV prevalence, in 
contrast to that in females, remains close to constant after the peak-prevalence.(Smith et 
al. 2011; Tota et al. 2011) 
 
Furthermore, anal HPV infection in healthy individuals has also gained scientific focus. 
Although most studies have studied HPV prevalence in HIV positive patients, a few 
studies have examined HPV in healthy individuals. In a longitudinal cohort study of 
healthy women in Hawaii, 70% of the studied women had >1 anal HPV infection 
during follow-up, and the majority cleared the infections swiftly. Furthermore, the 
investigators also stated that the anal and cervical HPV infections seemed to occur 
consecutively.(Goodman et al. 2008; Shvetsov et al. 2009; Goodman et al. 2010) In 
another Italian study, 28% of the investigated healthy sexually active women were 
infected with anal HPV; and similar figures were observed in the above-described 
Hawaii cohort at baseline.(Hernandez et al. 2005; Pierangeli et al. 2012) However, in 
heterosexual men, the prevalence of anal HPV infection has been reported to generally 
be low (<10%).(Vardas et al. 2011) 
 
In addition, HPV prevalence in oral specimens has also been examined and so far the 
data suggest that <10% of healthy individuals have an oral HPV infection. However, 
also here there is a variation in HPV prevalence and different detection techniques are 
used (Kreimer et al. 2010; Rautava et al. 2011; Du et al. 2012; Gillison et al. 2012) 
 
 
 
1.1.9 HPV associated malignant tumours and screening programs 
The most commonly studied HPV associated malignant neoplasia is cervical cancer, 
where 83-99.7% of the cases have been suggested to be HPV positive.(Smith et al. 
2007; de Sanjose et al. 2010; Li et al. 2011) On a regional level, similar numbers (92%) 
have been suggested in the county of Stockholm, Sweden.(Du et al. 2011) 
Nevertheless, other malignancies have also been associated with HPV over the years, 
including cancer of the anus (∼80% HPV positive (De Vuyst et al. 2009; Hoots et al. 
2009)), the vulva (∼40% HPV positive (De Vuyst et al. 2009)), the vagina (∼80% (De 
Vuyst et al. 2009)), the penis (∼40% HPV positive (Tota et al. 2011)) and the head and 
neck region (discussed in 1.2.5). Many of these tumours are preceded by pre-stages 
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e.g.: cervical intraepithelial neoplasia (CIN) in cervical cancer, vulvar intraepithelial 
neoplasia (VIN) in vulvar cancer and anal intraepithelial neoplasia (AIN) in anal 
cancer. So far however, no pre-stages have been identified in head and neck cancer. In 
addition, other HPV associated tumour sites such as e.g. lung and oesophageal cancer 
has been suggested, but here the role of HPV is still inconclusive.(Lofdahl et al. 2012; 
Yanagawa et al. 2013) 
 
Cervical cancer is today the only HPV associated disease that is included in a screening 
program, although there have been discussions to initiate screening-programs for some 
HPV associated tumours, e.g. for anal cancer.(Pierangeli et al. 2012) A systematic 
screening program for cervical cancer was initiated already in the 1960’s in Sweden, 
and has proven to reduce the incidence of the cancer by 35-75%.(Bergstrom et al. 
1999; Sigurdsson 1999; Hemminki et al. 2002) However, the previously most often-
used method, the Pap smear test, has low sensitivity and specificity for pre-stages of 
cervical cancer. Therefore, alternative methods with potentially higher sensitivity have 
been proposed, e.g. liquid-based cytology – in which cells are suspended and spread in 
a thin uniform manner on a slide to facilitate microscopic interpretation.(Arbyn et al. 
2008) Today it is questionable if Liquid-based cytology is indeed more sensitive than 
the classical Pap smear for cytology, but it does also offer the possibility to test for 
HPV status.(Strander et al. 2007; Arbyn et al. 2008; Froberg et al. 2013) Previously, 
HPV tests were controversial, and it was proposed that although detecting HPV was 
more sensitive, it was also less specific for detecting pre-stages of cervical cancer 
(CIN-II+).(Cuzick et al. 2006) Today, in many regions, HPV testing is gradually being 
introduced as a primary screening methods for women above 30 or 35 years of age, 
when genital HPV infection is less common in the general population as for those 
below 30.(Gyllensten et al. 2012) 
	  
	  
	  
1.1.10 Interactions with the immune system 
HPV has similar to pathogens in general also developed mechanisms to avoid the 
immune system and, thus, avoid immune clearance.  The expected human response to a 
viral infection is - indeed - described better elsewhere, and here only a brief and 
simplified recapitulation will be given. 
 
1.1.10.1 General immune response 
 
Keratinocytes, or other cells, may upon viral infection start to secrete pro-inflammatory 
cytokines, to attract antigen-presenting cells, such as dendritic cells (DCs) and 
macrophages. In addition, immature DCs - constantly sampling the surroundings for 
pathogens by pattern recognition receptors (PRR) - may engulf viral products. Upon 
DC activation, DCs mature and start to migrate to the regional lymph nodes and the 
foreign proteins within the DCs are degraded to peptides. These peptides are then 
presented on the major histocompatibility complex (MHC – often referred to human 
leukocyte antigen, HLA, in humans). Through presentation of peptides on MHC class I, 
or MHC class II antigens respectively, DCs bind to cytotoxic T cells (CTLs) or helper 
T-cells, in the presence of co-stimulatory molecules and bind to, interact with, and 
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activate their respective CD8+ or CD4+ receptors. Activated CD4+ T-cells start to 
proliferate and may mature into Th1 or Th2 cells depending on the cytokine 
environment. A milieu with IFN-γ drives Th1 cell production, while IL-10 and IL-4 
inhibit Th1 cell production and promote the formation of Th2 cells. In a viral infection, 
a Th1 response is desired, which can, by e.g. the secretion of IFN-γ, induce maturation 
of CD8+ CTLs and activate macrophages and NK-cells.(Abbas et al. 2004) 
Nevertheless, HPV usually successfully constrains and inhibits the immune response by 
different mechanisms, which will further be described below.   
 
 
1.1.10.2 Escaping the immune recognition by location of infection 
 
As mentioned above, the HPV replication cycle is highly regulated and limited to 
differentiating keratinocytes, as discussed in section 1.1.5. Subsequently, HPV does not 
exhibit a blood borne phase and there is no obvious cytolysis, when the viral particles 
are released.(Tindle 2002) Additionally, due to sub-optimal codon usage by HPV, the 
viral proteins are kept low.(Zhao et al. 2005) Therefore, taken together, the immune 
system has a low chance to detect the infection.  
 
Furthermore, data also suggest that the antigen presenting cells (APCs) in the 
epidermis, the Langerhans cells (LCs), are not activated by uptake of the HPV capsid, 
in contrast to the DCs in the dermis.(Fausch et al. 2002; Fausch et al. 2003; Da Silva et 
al. 2007) This way, the virus is able to hide from the immune system as long as the 
infection is localised to the epidermis. Moreover, it has also been proposed that the 
local cytokine milieu (e.g. TGF-β and IL-10), produced by the keratinocytes that are 
present when LCs mature, may promote LCs to polarise towards Th2 type 
immunity.(Brinkman et al. 2007) Such Th2 type immunity would result in an 
ineffective response against HPV infected cells. 
 
Lastly, the antiviral and immune-stimulatory type -1 interferons (IFN-α and IFN-β) are 
inhibited by the HPV oncogenes. HPV E7 has been suggested to inhibit IFN-α signal 
transduction by binding of the interferon regulatory factor 9 (IRF-9) and preventing its 
translocation from the nucleus. Another function of E7 that has been proposed is the 
ability to inhibit IRF-1 activation of the IFN-β promoter. HPV18E7 has also been 
described to reduce IRF-1 genes, such as TAP-1 and monocyte chemotactic protein-1 
(MCP-1). The HPV E6 protein has, on the other hand, been described to inhibit IFN-α 
signalling by preventing transcription through inhibition of IRF-3.(Tindle 2002; Stanley 
2012) An interesting comment to the ability of HPV to down-regulate IFN-α and its 
importance in immune evasion is that IFN-α is used to treat genital warts. However, 
not all patients respond to this treatment, and there are data showing that responders 
have lower E7 levels than those that do not respond.(Arany et al. 1995) 
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1.1.10.3 HPV and antigen presenting machinery (APM)  
 
1.1.10.3.1 MHC class I and class II 
  
Recognition of viral peptides on MHC antigens is crucial for clearance of virally 
infected cells. In the majority of cases focus is directed towards the presentation of viral 
peptides on MHC class I molecules and recognition by CTLs. Nevertheless, prior to the 
presentation of viral peptides, a cascade of events takes place in the infected cell. 
Intracellular proteins, foreign as well as self-proteins, are degraded by the proteasome 
in the cytosol. (The activity of the ubiquitin-protease pathway may be modulated by 
IFN-γ, which induces proteasome sub-units (e.g. LMP-2, -7 and -10) as well as some 
proteasome activators.) After degradation, the peptides are transported and translocated 
to the ER by TAP-1 and TAP-2 molecules, with the purpose to be loaded to an MHC 
class I molecule. In parallel, the formation of MHC molecules is continuously on 
going, with the MHC class I heavy chain (HC) translocation to the ER lumen by Sec61. 
The HC binds to the chaperones Calnexin and BiP, and is thereby assisted in 
appropriate folding and the binding to the beta2 microglobulin (β2m) chain. Thereafter, 
Calnexin is dissociated and replaced by Calreticulin and Erp53, which stabilises the 
MHC molecule. Tapasin also binds to MHC class I molecules linking them with TAP1 
and TAP2 proteins and, thereby allowing for building up of the peptide-loading 
complex. After the loading of MHC class I molecules with peptides, the whole complex 
is transported to the cell surface through the ER and Golgi. Sub-optimal loading of 
peptides to the complex, results in that MHC class I molecules exiting in the ER are 
degraded.(Seliger et al. 2000; Abbas et al. 2004; Seliger 2012) 
 
As stated above, MHC class II antigens also bind peptides, and in this case mostly 
extracellular peptides, however since MHC class II antigens are almost exclusively 
expressed on APCs, e.g. monocytes, dendritic cells and B-cells this process is not 
clarified here in more detail.(Abbas et al. 2004) Nevertheless, as described later, HLA 
class II expression may be observed in some malignancies and has been shown to 
enhance tumour-specific immunity by bypassing the classical MHC class I pathway. 
(Glew et al. 1992; Glew et al. 1993; Armstrong et al. 1997; Armstrong et al. 1998; 
Zehbe et al. 2005) 
 
 
1.1.10.3.2 HPV and MHC class I 
 
Similar to many viruses, HPV has developed mechanisms to interact with and down-
regulate the antigen presenting machinery (APM). However, in contrast to other viruses 
that may interfere at any of the above-described steps in the APM, HPV-16 has only 
been reported to interfere with MHC class I.(Hansen et al. 2009) Previous reports have 
shown the ability of the HPV E5 protein, which mainly is located in the Golgi, to bind 
the HC of MHC class I (independent of haplotype) and to retain it in the Golgi, 
however when the tumour cells were treated with interferon, the E5 mediated effect 
was lost.(Ashrafi et al. 2005; Ashrafi et al. 2006a; Ashrafi et al. 2006b; Campo et al. 
2010) Other reports have investigated the role of HPV-16 E7, and found that the viral 
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protein may cause repression of the MHC class I promoter, leading to lower MHC class 
I levels on cell surface. Consequently, blocking of E7 with siRNA in SiHA and CaSki 
cell lines, increased MHC surface levels, while induction of E7 reduced the levels. 
MHC class I down-regulation increased NK-cell killing.(Georgopoulos et al. 2000; Li 
et al. 2006; Bottley et al. 2008) 
 
1.1.10.3.3 MHC class I and II expression in HPV associated malignancies 
 
Down-regulation of MHC class I expression is a well-known tumour evasion 
mechanism and may occur relatively frequently in human neoplasias, including e.g. 
breast, lung, ovarian, cervical and head and neck cancer.(Keating et al. 1995; Vitale et 
al. 1998; Atkins et al. 2004; Ogino et al. 2006; Ramnath et al. 2006; Han et al. 2008; 
Mehta et al. 2008) Moreover, loss of or down regulation of MHC class I expression has 
also been correlated with disease progression. Thus, in cervical cancer, MHC class I 
and II antigen expression is reported to decrease with disease progression as well as 
with metastatic disease.(Ryu et al. 2001) Similar results have been observed in other 
malignancies, e.g. ovarian cancer and melanoma.(Le et al. 2002; Carretero et al. 2008) 
These data are in line with older data, in which MHC class I was down regulated in 
metastasised neoplastic cells, as compared to primary tumour cells. Moreover, the 
metastatic down regulation was accompanied by loss of TAP-1 expression.(Cromme et 
al. 1993; Cromme et al. 1994b) Although no HPV proteins have been shown to interact 
with the APM proteins described above, studies have shown deregulated levels of e.g. 
LMP and TAP molecules in cervical cancer.(Cromme et al. 1994a; Evans et al. 2001; 
Mehta et al. 2008) 
 
Nonetheless, down-regulation of HLA class I molecules has also frequently been linked 
with a poor clinical outcome in a variety of human tumours, e.g ovarian and head and 
neck cancer.(Meissner et al. 2005; Ogino et al. 2006; Han et al. 2008) However, in 
contrast, loss of HLA class I expression has also been linked to a favourable prognosis 
in some cancers, e.g. colon and breast cancer, as well as HPV associated cervical and 
head and neck neoplasias.(Madjd et al. 2005; Watson et al. 2006; Jordanova et al. 
2008; Nasman et al. 2013) Frequently given explanations for the favourable prognosis 
in patients with HLA class I deregulated tumours often include alternative immune 
recognition possibilities, and often refer to NK-cell activity and the recognition of lack 
of MHC class I, i.e. none-self.(Jordanova et al. 2008) Similarly, explanations often 
given for the favourable prognosis in HLA class I expressing tumours often include an 
intact antigen presenting machinery that may induce an immune recognition.(Meissner 
et al. 2005)(Pages et al. 2011) However, it is important to note, that irrespective of 
possible mode for immune recognition, the prognosis is always poor if the patients are 
not treated.  
 
1.1.10.3.4 Non-classical MHC molecules in HPV associated malignancies  
 
It has been suggested that overexpression of non-classical HLA class I molecules -E 
and -G, sometimes observed in tumours, may modulate the immunological response. 
Hence, such overexpression has been correlated to tumour progression, although the 
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opposite has also been observed.(Wischhusen et al. 2007; Yie et al. 2007a; Yie et al. 
2007b; Yie et al. 2007c; Amiot et al. 2011) HLA-G, that is normally expressed during 
embryonic development, may be up-regulated in e.g. renal cancer, and has in vitro been 
reported to inhibit the cytolytic functions of NK and T-cells.(Ibrahim et al. 2001; 
Carosella et al. 2011) Moreover, HLA-E, frequently overexpressed on tumour cells, has 
e.g. in cervical cancer been linked to tumour progression.(Marin et al. 2003; Goncalves 
et al. 2008) However, in HPV associated tonsillar carcinoma, neither the expression of 
HLA-E nor HLA-G influenced clinical outcome.(Nasman et al. 2013) 
 
1.1.10.3.5 HPV and T-cell response 
 
It has been suggested, and also to some extent stated above, that an effective T-cell 
response comprising both virus-specific CD8+ CTL and CD4+ IL-2 and IFNγ 
producing Th1 cells are required to eradicate HPV infected cells.(van der Burg 2012) 
This statement is consistent with that HPV induced progressive diseases are associated 
with a lack of such strong T-cell responses against the early viral proteins; and the 
tumours are often infiltrated with immune suppressive cells. More specifically, it has 
been shown that T-cells in cervical cancer do not produce granzyme B, that is crucial 
for the induction of target cell apoptosis, but do express PD-1, as a sign of 
exhaustion.(Bontkes et al. 1997; Karim et al. 2009; van der Burg et al. 2011) 
Moreover, the expression of CXCL12 has also been described to increase by disease 
severity in cervical cancer – resulting in even higher levels of Tregs.(Jaafar et al. 2009)  
 
Consequently, in patients with cervical cancer, when observed, the presence of an 
HPV-specific Th1 response has been associated with a better clinical outcome and a 
better treatment response. Likewise, a high infiltration of granzyme B producing CD8+ 
cells in CIN has been linked to spontaneous regression in some patients.(van der Burg 
2012) Moreover, the degree of CD8+ tumour infiltrating lymphocytes (TILs), or only 
TILs by itself, have been shown to correlate favourably to clinical outcome in a variety 
of tumours, including HPV associated malignancies.(Aaltomaa et al. 1992; Bethwaite 
et al. 1996; Sato et al. 2005; Galon et al. 2006; Nedergaard et al. 2007; Piersma et al. 
2007; Nasman et al. 2012) Similarly, a high infiltration of Foxp3+ TIL has been linked 
to a worse prognosis in many different tumours, but also to a favourable outcome in 
others.(Ichihara et al. 2003; Badoual et al. 2006; Bates et al. 2006; Carreras et al. 2006; 
Salama et al. 2009; Shah et al. 2011). 
 
 
1.1.10.3.6 HLA class I and II alleles and risk of HPV associated cancer 
 
In a variety of diseases, studies have linked HLA alleles and their variants to the risk of 
developing a disease or to the prognosis of the disease. One example is that HLA-B27 
is linked to an increased risk of developing Mb Bechterew or reactive 
arthropathy.(Sims et al. 2004) Correspondingly, similar attempts have been made to 
link HPV related malignancies to certain HLA types. 
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In this context, some words about the nomenclature of HLA may be of interest. The 
nomenclature of HLA class I also includes a letter that indicates the gene (e.g. -A) and 
a digit that indicates the allele. HLA-A, -B and -C are often referred to as “classical” 
genes, while the others, e.g. HLA-E and -G, are often referred to as “non-classical” 
genes. The loci of MHC class II genes are named with 3 letters; 1st: indicates the class 
(D), 2nd: indicates the family (M, O, P, Q and R) and 3rd: indicates the chain (A=α or 
B=β). Moreover, the first digit that follows the letter indicates the gene, which is 
followed by an asterisk and a number – that indicates allelic variants.(Marsh et al. 
2010)  
 
Most studies with regard to association between HLA and HPV related diseases have 
been made in cervical cancer, but the data are not completely consistent. Here only a 
few of many reports linking HLA alleles to an increased or a decreased risk for cervical 
cancer are presented. In some reports the presence of e.g. DRB1* is associated to an 
increased risk of developing cervical cancer, however the data is hard to overview. 
(Beskow et al. 2001; Hildesheim et al. 2002; Beskow et al. 2005; Chan et al. 2006; 
Castro et al. 2007; Ades et al. 2008; Madeleine et al. 2008; Castro et al. 2009; 
Hernandez-Hernandez et al. 2009; Matsumoto et al. 2012) Protective associations have 
also been shown. In a meta-analysis published some years ago, a protective effect of 
DRB1*1301 and DQB1*0603 against the development of cervical cancer was 
demonstrated.(Hildesheim et al. 2002)  
 
 
 
	  
1.1.11 Vaccines 
Today, there are two commercially available prophylactic vaccines (Cervarix®, Glaxo-
SmithKline, UK and Gardasil®, Merck, USA), both covering the two most common 
HPV types (16 and 18) worldwide in cervical cancer (∼70%). However, up to date, no 
therapeutic vaccine has been introduced on the market, although extensive efforts have 
been made to develop such vaccines. Below, a brief summarization of the knowledge of 
the vaccines will be presented. 
 
 
1.1.11.1 Prophylactic vaccines 
 
The two today approved prophylactic HPV vaccines are both based on virus like 
particles (VLP), which are formed by self-assembled L1 proteins (discussed in 1.1.5). 
Gardasil®, which was FDA-approved in 2007, is a quadrivalent vaccine against two 
high-risk HPV types (HPV 16 and 18) and two low-risk HPV types (HPV 6 and 11). 
Cervarix, which was introduced some months later, is a bivalent vaccine against the 
high-risk HPV types 16 and 18. Although both vaccines consist of VLPs, the adjuvant 
that is administered with the VLPs and the production setting differs. In Gardasil®, the 
adjuvant consists of amorphous aluminium hydroxyphosphate sulfate and the vaccine is 
produced in yeast; in Cervarix® the adjuvant consists of aluminium hydroxide and the 
vaccine is produced in insects cells. Cervarix also contains monophosphoryl lipid A 
(MPA), leading to an activated innate immune response.(Schiller et al. 2008) Studies 
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have shown a very high efficacy in both vaccines (∼100% prevention of HPV-16 and 
HPV-18 associated CIN III after 4-years) and that there is also some cross-protection 
against some other non-covered high-risk HPV types.(Munoz et al. 2010; Lehtinen et 
al. 2012; Malagon et al. 2012) Strong in vitro and in vivo data, as well as data from 
clinical trials suggests that the effector mechanism of both vaccines is mainly attributed 
to antibodies. Since Cervarix mainly induces a T helper 1 response, while Gardasil 
mainly induces a T helper 2 response, but the vaccines efficacies are basically the same, 
it is has been postulated unlikely that CD4 T cell effector functions play a major role in 
the protection. Likewise, although a strong CD8 T cell response against L1 is 
generated, it is regarded unlikely that cytotoxic T-cells are important protective 
mediators, especially, since L1 is expressed late in the viral life cycle (discussed in 
section 1.1.5).(Schiller et al. 2012) However, others have disagreed on this statement. 
(Dalianis 2013, personal communication) 
 
As stated above, antibody mediated protection is suggested as the most important, and 
titres after HPV VLP vaccination are 80-100 fold higher that those observed after 
natural infection.(Frazer 2010) These high titres appear to remain high over time in 
both vaccines, but recent data imply that titres generated by Cervarix are more stable 
than titres generated by Gardasil. However, it is important to note that different assay 
methods have been used in the evaluations of the vaccines and therefore the results 
from the two vaccines cannot be directly compared.(Einstein et al. 2009; Schiller et al. 
2009; Romanowski 2011) Moreover, there is an on-going debate on whether high 
antibody levels actually result in longer duration of protection. Based on the acquisition 
of higher antibody levels some have therefore argued that Cervarix is superior to 
Gardasil, while others have claimed the role of memory B-cells – which are induced in 
both vaccines (Villa 2011) – and stated that the vaccines should be considered as equal. 
 
Nevertheless, up to date, no studies have investigated the preventive efficacy of the 
vaccines in head and neck cancer, and oropharyngeal cancer more specifically. 
However, some authors, e.g. Gillison 2008, have suggested the possibility of a 
protective vaccine effect in oropharyngeal cancer.(Gillison 2008) In her argumentation, 
also used by others, she refers to studies in which researchers have observed a 
protective effect against canine oral papillomavirus (COPV) infection in dogs after 
vaccination with VLPs.(Suzich et al. 1995) Other arguments used are the fact that oral 
HPV IgG specific antibodies have been detected in HPV seropositive HIV infected 
patients, in women with cervical cancer and in individuals attending a dental 
clinic.(Cameron et al. 2003; Buchinsky et al. 2006; Marais et al. 2006)  
 
Conversely, others have been more guarded in their opinions. Since an intramuscular 
injection of the vaccine primarily induces an IgG response, while an IgA response 
should be more appropriate in a mucosal infection, the mode of action of the vaccines 
have been under discussion.(Mestecky et al. 2010) Two possible mechanisms have 
been proposed: (1) transduction of IgG antibodies (only described in cervix) and (2) 
exudation of antibodies to surfaces, where HPV binds to the basal membrane. It has 
however been suggested that exudation may play a great role, because the quadrivalent 
vaccine gives an excellent protection against genital warts (also in males) on cornified 
skin  – a site where transfusion is very unlikely to occur.(Schiller et al. 2012) However, 
in oropharyngeal cancer, these above-described mechanisms are poorly studied.  
  22 
 
 
1.1.11.2 Therapeutic vaccines 
 
Up to date, there are no commercially registered therapeutic vaccines against HPV 
induced diseases in the clinic. However, many attempts have been made based on the 
hypothesis that tumours driven by foreign HPV antigens should easily be cleared by the 
immune system upon an induction of a strong Th1/cytotoxic T-cell response. 
Consequently, there should be a considerable possibility to clear HPV positive tumours 
by a therapeutic cancer vaccine. However, as discussed above (1.1.10), HPV could 
create an immunosuppressive milieu that may be hard to overcome. Furthermore, since 
HPV indirectly has a mutagenic potential, it could induce changes, resulting in that the 
tumour becomes more resistant to the immune system for other reasons. 
 
Nonetheless, the choice of target is crucial and the early proteins E6 and E7 are often 
used. Therapeutic vaccines can be divided into 5 main categories; (1) peptide vaccines 
(2) protein vaccines (3) viral vector based vaccines (4) DNA vaccines and (5) dendritic 
cell (DC) based vaccines. Peptide and protein vaccines are easy to administer, but they 
often exhibit a low immunogenicity and require adjuvants, e.g. toll-like receptor 
ligands. In addition, peptide vaccines are mainly restricted to retained expression of 
specific HLA class I antigens, while protein-based vaccines, which can be potentially 
be processed into several peptides are not equally restricted to one specific HLA class I 
antigen. Viral vector based vaccines are in general more immunogenic, but pre-existing 
immunity and safety concerns are considered as drawbacks. Another vaccine approach 
is the use of DNA vaccines, which also are generally considered as safe and easy to 
deliver, but with low immunogenicity. Finally, the DC vaccine approach is also 
considered as safe, but is costly and time consuming. Below, some of the promising 
therapeutic vaccine approaches will be described in more detail. 
 
Although an HPV specific CTL response has been detected in some patients included 
in therapeutic peptide vaccine trials against high-grade CIN/VIN or vulvar/cervical 
cancer, no correlation to clinical outcome has been observed.(Steller et al. 1998; van 
Driel et al. 1999; Muderspach et al. 2000; Ressing et al. 2000) Taking the data 
together, the use of short peptides has so far been discouraging. It is possible, that this 
poor outcome is partly due to the very specific HLA class I restriction of short peptides. 
More recently therefore, long peptides have gained more and more interest. Data from 
the groups of van der Burg and Melief suggest that the use of long synthetic peptides 
that span the whole HPV 16 E6 and E7 sequences may induce HPV specific CD4+ and 
CD8+ T-cell responses and also clinical responses in VIN. More specifically, after 
vaccination of women with VIN III with long HPV E6/E7 peptides, at the 12-months 
follow-up, complete responses and clinical responses were obtained in 9/19 and 15/19 
respectively of the women, and were associated with a CD4+ and CD8+ T-cell type 1 
response.(Kenter et al. 2008; Welters et al. 2008; Kenter et al. 2009; Welters et al. 
2010) 
 
Fused viral proteins (so-called fusion proteins) have also shown promising results in 
some but not all studies. As examples, Frazer el al used a fusion protein between E6 
and E7 and observed decreased viral load in the vaccinated group, while Kaufmann et 
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al. used HPV 16 E7L1 chimeric VLPs and found no significant clinical effect.(Frazer et 
al. 2004; Kaufmann et al. 2007) Another fusion-protein vaccine approach is to combine 
a viral protein with a foreign, more immunogenic, protein, e.g. Hsp 65 from 
Mycobacterium Bovis. However, such studies have so-far shown diverse 
results.(Goldstone et al. 2002; Corona Gutierrez et al. 2004; Hallez et al. 2004) 
 
 
 
1.1.12 Additional treatment modalities 
Although the above-mentioned therapeutic vaccination may sound promising as a 
treatment modality, present clinically available treatment regimes in HPV associated 
malignancies are today only oncological treatment and surgery (discussed in section 
1.2.8). However, novel and more specific therapies are emerging and possibly soon 
entering the everyday clinical scene. Such treatment modalities may include adoptive 
T-cell transfer of HPV specific T-cells, small molecules interfering with e.g. the viral 
protein E6 and drugs that modulate the immune response.(Stern et al. 2012) Although 
the mechanisms used in these treatments differ, they all have HPV as a direct/indirect 
target in common. Below some examples will be discussed.  
 
 
 
 
1.1.12.1 Cidofovir 
 
In Sweden Cidofovir is marketed as Visitide® and has CMV induced retinitis in AIDS 
patients as the only indication. The drug is an acyclic nucleoside phosphate and inhibits 
CMV replication selectively by inhibiting the viral DNA polymerase at concentrations 
8-600 times lower than what is required to inhibit human DNA polymerases.(FASS.se 
2013) However, Cidofovir has also been shown to reduce HPV E6 and E7 expression 
in vitro in 2 HPV-16 positive cell lines and to reduce the metastatic potential in 
vivo.(Amine et al. 2009) Furthermore, small studies using topical treatment with 
Cidofovir in pre-stages to vulvar or cervical cancer (VIN and CIN) have shown some 
promising results.(Snoeck et al. 2000; Tristram et al. 2005) 
 
 
1.1.12.2 Imiquimod 
 
Imiquimod, marketed as Aldara® in Sweden, is suggested to act through the Toll-like 7 
receptor and thereby e.g. induce IFN-α and tumour necrosis factor beta (TNF-β). 
Studies have also suggested that topically applied Imiquimod may activate LCs in the 
epidermis, and upon such stimulation they may migrate to the lymph nodes and activate 
the adaptive immune system. The approved indications in Sweden for Imiquimod are 
actinic keratosis, basal cell carcinoma and condylomata accuminata.(FASS.se 2013) 
 
Nevertheless, topical application of Imiquimod alone (discussed below) or as a 
combination therapy together with photodynamic therapy or together with a therapeutic 
HPV vaccine has been used outside its indications in clinical trials in VIN 
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patients.(Winters et al. 2008; Daayana et al. 2010) Two randomized controlled studies 
have recently been published, showing a favourable response in VIN patients treated 
with only Imiquimod compared to placebo.(Mathiesen et al. 2007; van Seters et al. 
2008; Terlou et al. 2011) However, very few studies have examined Imiquimod 
treatment compared to surgery in VIN. In a retrospective study with a heterogenic study 
population by Bruchim et al, patients treated with surgery presented a better treatment 
response, but tended to relapse more frequently than those treated with 
Imiquimod.(Bruchim et al. 2007) Therefore, the role of Imiquimod in VIN and other 
HPV related pre-malignant diseases is still unknown and additional studies are needed.  
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1.2 OROPHARYNGEAL CANCER 
Head and neck cancer includes neoplasias of the sub-sites of the mobile tongue, the lip, 
the oral cavity, the oropharynx, the salivary glands, the larynx, the hypopharynx, the 
epipharynx, the sinuses and the ear.(Munck-Wikland 2012) Oral and oropharyngeal 
malignancies represent 3-5% of all diagnosed cancers in the Western world, and are 
more common in some parts of Asia, where they represent up to 40% of all diagnosed 
cancer cases.(Parkin et al. 2002; O'Sullivan 2008) A common first symptom of 
oropharyngeal cancer is a lump on the patient’s neck; consequently, these patients are 
often diagnosed at late stages. Other symptoms may include a sore throat, swallowing 
difficulties and pain.(Licitra et al. 2002; Hammarstedt 2008) 
 
Classical risk factors for oropharyngeal cancer are smoking, alcohol abuse and betel nut 
chewing, but during the last decades an association of HPV infection and 
oropharyngeal cancer was detected.(Gillison et al. 2000; Mellin et al. 2000; Klussmann 
et al. 2001; Mellin et al. 2002; Genden et al. 2003; Ritchie et al. 2003; Hammarstedt et 
al. 2006) Based on some of those studies and additional evidence, in 2007, HPV was 
acknowledged by the IARC, as an additional risk factor for oropharyngeal cancer. 
(IARC-Monographs 2007) 
 
 
 
1.2.1 Anatomy and histology of normal oropharynx 
The oropharynx is located in the middle part of pharynx, and contains four distinct sub-
sites: (1) the palatine tonsillar fossa and pillars, (2) the tongue base (3) the soft palate 
and (4) the pharyngeal walls. The oropharynx is covered by squamous epithelium. The 
lingual tonsil, the palatine tonsils and the inferior proportion of the nasopharyngeal 
tonsils (the adenoid pad) are often referred to as the Waldeyer’s ring, since these 
structures form a circumferential ring in the oropharynx (Figure 6). The histology of the 
epithelium in the Waldeyer’s ring is often referred to as “lymphoepithelium”, in which 
the squamous epithelium invaginates and merges the underlying lymphoid tissue and 
forms crypts. These crypts are highly prevalent in the tonsils (10-30 crypts per tonsil), 
but are more rarely observed in the tongue base.(Syrjanen 2004; Duvvuri et al. 2009) 
 
 
 
 
 
Figure 6. The Waldeyer´s ring, location and structures. 
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1.2.2 Oropharyngeal cancer – classification 
Although oropharyngeal cancer may appear as a well-defined sub-type of head and 
neck cancer, different classification systems and different classification codes have 
been used in the literature, and in some scientific papers, oropharyngeal cancer is not 
defined at all.(Ritchie et al. 2003; D'Souza et al. 2007; Hammarstedt et al. 2007; 
Chaturvedi et al. 2008; Nasman et al. 2009) The standard classification of diseases is 
the International Classification of Diseases (ICD) system, which has developed and 
refined over the years and since 1994 ICD-10 is used. When the Swedish Cancer 
Registry was initiated in 1958, the ICD-7 was used and it is still used today. 
(Hammarstedt et al. 2007) Therefore, in order to compare e.g. incidence trends of 
oropharyngeal cancer over decades when using the Swedish Cancer Registry, all ICD-
10 codes must be translated into ICD-7, thus making it somewhat complicated (Table 
2). 
 
 
 
Table 2. International classification of diseases translator  
 Codes that are underlined are used in paper I and III-V of this thesis 
   
 
 
code definition code definition code definition code definition
141.6
Malignant-neoplasm-of-
lingual-tonsil C02.4
Malignant-neoplasm-of-
lingual-tonsil
146.0
Malignant-neoplasm-of-the-
tonsils C09.9
Malignant-neoplasm-of-
tonsil,-unspecified
146.1
Malignant-neoplasm-of-
tonsillar-fossa C09.0
Malignant-neoplasm-of-
tonsillar-fossa
149.1
Malignant-neoplasm-of-
Waldeyer's-ring C14.2
Malignant-neoplasm-of-
Waldeyer's-ring
146.2
Malignant-neoplasm-of-
tonsillar-pillars------------
(anterior-and-posterior)
C09.1
Malignant-neoplasm-of-
tonsillar-pillar------------
(anterior-and-posterior)
146.3
Malignant-neoplasm-of-
vallecula-epiglottica C10.0
Malignant-neoplasm-of-
vallecula
146.4
Malignant-neoplasm-of-
anterior-aspect-of-epiglottis C10.1
Malignant-neoplasm-of-
anterior-surface-of-epiglottis
146.5
Malignant-neoplasm-of-
junctional-region-of-
oropharynx
C10.8
Malignant-neoplasm-of-
overlapping-sites-of-
oropharynx
146.6
Malignant-neoplasm-of-
lateral-wall-of-oropharynx C10.2
Malignant-neoplasm-of-
lateral-wall-of-oropharynx
146.7
Malignant-neoplasm-of-
posterior-wall-of-oropharynx C10.3
Malignant-neoplasm-of-
posterior-wall-of-oropharynx
146.8
Malignant-neoplasm-of-
other-specified-sites-of-
oropharynx
C09.8
Malignant-neoplasm-of-
overlapping-sites-of-tonsil
145.9
Malignant-neoplasm-of-------
oral-mesopharynx,-----------------------
Part-unspecified
146.9
Malignant-neoplasm-of-
oropharynx,--------------------------
Part-unspecified
146.9
Malignant-neoplasm-of-
oropharynx,-------------
unspecified-site
C10.9
Malignant-neoplasm-of-
oropharynx,-------------
unspecified
ICD)9*code ICD)10*code
145.0 146.0
Malignant-neoplasm-of-----
oral-mesopharynx,--------------------
Tonsil---------------------------
(excluding-pillars)
Malignant-neoplasm-of-
oropharynx,----------------------
Tonsils
145.7
Malignant-neoplasm-of------
oral-mesopharynx,------------------
Other-specified-parts-of-
mesopharynx
146.8
Malignant-neoplasm-of-
oropharynx,------------------------
Other-specified-parts
ICD)7*code ICD)8*code
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Clinical staging of oropharyngeal cancer is made according to the TNM-classification 
(International Union Against Cancer (UICC)). The latest classification system (7th 
Edition) is based on the size of the primary tumour (T-stage); presence, size, numbers 
of, and localisation of regional metastasis to lymph nodes (N-stage); and presence of 
distant metastasis (M-stage) (Table 3). The TNM-classification is then divided into 
stage I-IV (Figure 7).(Sobin et al. 2009) 
 
Table 3.	  TNM classification of OSCC according to UICC 
 
Figure 7. TNM and stage (I-IVb) classification according to UICC 
 
Patients with M1 (distant metastasis present) are classified as stage IVc 
  
N0 I II III IVa IVb
N1 III III III IVa IVb
N2a IVa IVa IVa IVa IVb
N2b IVa IVa IVa IVa IVb
N2c IVa IVa IVa IVa IVb
N3 IVb IVb IVb IVb IVb
T1 T2 T3 T4a T4b
Definition Comments
TX Primary'tumour'can'not'be'assessed
T0 No'evidence'of'primary'tumour
Tis Carcinoma'in'situ
T1 Tumour'<2cm'in'greatest'dimension
T2 Tumour'>2cm'in'greatest'dimension
T3 Tumour'>4cm'in'greatest'dimension
T4a Moderately'advanced'local'disease Tumour'invades'the'larynx,'deep/extrinsic'muscle'of'the'
tongue,'medial'pterygoid,'hard'palate,'or'mandible
T4b Very'advanced'local'disease Tumour'invades'lateral'pterygoid'muscle,'ptergoid'palates,'
lateral'nasopharynx,'skull'base,'or'encases'the'carotid'artery
NX Regional'lymph'nodes'can'not'be'assessed
N0 No'regional'node'metastasis
N1 Metastasis'in'a'single'ipsilateral'lymph'node,'<3cm'in'greatest'
dimension
N2a Metastasis'in'a'single'ipsilateral'lymph'node,'>3cm'in'greatest'
dimension,'but'<6cm'in'greatest'dimension
N2b Metastasis'in'multiple'ipsilateral'lymph'nodes,'<6cm'in'greatest'
dimension
N2c Metastasis'in'bilateral'or'contralateral''lymph'nodes,'<6cm'in'
greatest'dimension
N3 Metastasis'in'a'lymph'node,'>6cm'in'greatest'dimension
MX Distant'metastasis'cannot'be'assessed
M0 No'distant'metastasis
M1 Presence'of'distant'metastasis
T
N
M
TNM.classification
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1.2.3 Histology 
Squamous cell carcinomas cover >90% of all oropharyngeal malignancies, but other 
rare types, e.g. arising from the minor salivary glands, may also occur. Other infrequent 
tumours of oropharynx may include sarcomas (radiation-induced or spontaneous) and 
lymphomas (most common in palatine tonsils).(Duvvuri et al. 2009) 
 
Histological studies suggest a unique entity of HPV related squamous cell carcinomas 
of the oropharynx, with non-keratizing carcinomas forming sheets, nests and trabeculae 
with pushing borders and a slight stromal response (Figure 8). In contrast, non-HPV 
associated oropharyngeal squamous cell carcinomas tend to form keratinizing tumours 
with polygonal (many sides) cells, rich of cytoplasm and distinct cell borders (Figure 
9).(El-Mofty et al. 2003; El-Mofty et al. 2006; Chernock et al. 2009) Other histological 
classifications, very often used, are grading of tumours as well, moderate, poorly 
differentiated and undifferentiated; or grading of the tumours as “basaloid” or “non-
basaloid”. In well-differentiated SCC, there is a close resemblance to normal epithelial 
cells and a prominent keratinization, but in in poor differentiated SCC there is only a 
slight similarity to normal epithelial cells and keratinization is extremely scarce. 
Subsequently, the presence of HPV has been linked to low grade as well as to basaloid 
lesions. 
 
 
 
1.2.4 Epidemiology 
Annually, in Sweden, there are around 200-250 newly diagnosed cases of OSCC and 
the dominant sub-sites are tonsillar squamous cell carcinoma (TSCC) and base of 
tongue squamous cell carcinoma (BOTSCC), accounting for >90% of the cases.(Åberg 
2012) While the incidence of head and neck cancer has generally decreased in Sweden, 
the incidence of OSCC has increased; and similar incidence trends have also been 
observed in many other Western countries. Moreover, this trend has been described to 
be most prominent in TSCC; in young (<60 years) and in male patients.(Frisch et al. 
2000; Shiboski et al. 2005; Hammarstedt et al. 2007; Ryerson et al. 2008; Braakhuis et 
al. 2009; Reddy et al. 2010; Blomberg et al. 2011; Hocking et al. 2011; Olaleye et al. 
2011; Saba et al. 2011; de Souza et al. 2012; Forte et al. 2012; McGorray et al. 2012; 
Åberg 2012) 
 
Figure 8. HPV related, non-keratizing 
squamous cell carcinoma.  
 
Figure 9. Non-HPV associated, keratizing 
squamous cell carcinoma with polygonal cells 
rich of cytoplasm and distinct cell borders. 
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1.2.5 Prevalence of and evidence for association to HPV infection 
1.2.5.1 Initial studies 
 
    In 1983, Syrjänen and Syrjänen and colleagues published the first data indicating that 
sub-groups of HNSCC could be associated with HPV infection.(Syrjanen et al. 1982; 
Syrjanen et al. 1983) Although the Syrjänens focused mostly on oral and laryngeal 
squamous cell carcinomas the data highlighted the concept of HPV in HNSCC. Their 
initiative, initiated very many studies on the association of HPV with HNSCC in 
different locations and eventually there was extensive evidence supporting the presence 
of HPV in OSCC. Therefore, in 2007, the International Agency of Research of Cancer 
(IARC) declared that “there is strong epidemiological evidence for the casual role if 
HPV16 in the etiology of cancer of the oropharynx and tonsil”.(IARC-Monographs 
2009)  
 
1.2.5.2 Prevalence of HPV in OSCC 
 
However, the prevalence of HPV in OSCC varies, not only between study cohorts and 
countries; alcohol and smoking habits in the study population, but also over decades, 
age of study population and by how OSCC is defined (ICD codes used). Another factor 
that may contribute to the variation in HPV prevalence is that different methods are 
presently used to define HPV positivity (discussed in section 1.1.7)  
 
Whereas a meta-analysis by Kreimer et al from 2005, including 27 studies and 969 
patients from 19 countries, stated that 35.6% of all OSCC are HPV positive and HPV16 
is the dominant type, there was a huge variation in the HPV prevalence figures 
reported. This is exemplified in that the HPV prevalence in TSCC was described to be 
as low as 12.6% in Taiwan, but as high as 79% of all TSCC cases in Stockholm, 
Sweden.(Kreimer et al. 2005; Tachezy et al. 2005; D'Souza et al. 2007; Kim et al. 
2007; Charfi et al. 2008; Chien et al. 2008; Nasman et al. 2009; Hannisdal et al. 2010; 
Ribeiro et al. 2011; St Guily et al. 2011) Moreover, there is also evidence that the HPV 
prevalence has increased in OSCC during the last decades, suggesting that the above-
mentioned increase in OSCC is due to HPV infection.(Hammarstedt et al. 2006; 
Ernster et al. 2007; Nasman et al. 2009; Attner et al. 2010) Accordingly, as discussed 
in paper I of this thesis, the HPV positive TSCC has increased 7-fold between 1970-
2006 in Stockholm, while the incidence of HPV-negative TSCC has decreased from the 
1980’s.(Nasman et al. 2009) Another interesting study by Marklund and colleagues 
suggest that HPV prevalence in OSCC is highly dependent on which sub-site in OSCC 
that is studied. Thus, HPV prevalence has been reported to vary from only 16% in 
cancer of the oropharynx (ICD-10 C10) to up to 79% in TSCC (ICD-7 145.0) during a 
similar time period.(Nasman et al. 2009; Marklund et al. 2012) 
 
There are very few studies examining the role of HPV in HIV infected OSCC patients. 
Some studies have proposed an elevated risk for developing OSCC in HIV infected 
patients, but this increase could potentially be explained by higher rates of smoking or 
by that HPV and HIV share sexual risk factors.(Grulich et al. 2007; Patel et al. 2008) 
Nonetheless, a recent published study investigates the risk of being infected with HPV 
in the oral cavity in HIV infected/non-infected individuals. The authors conclude that 
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HIV infected individuals have an increased odds of being infected with HPV positive 
and that HIV infected and non-infected individuals have different risk factors. Whilst 
presence of HPV in non-HIV infected individuals were associated to higher numbers of 
recent oral sex partners, HPV infection in HIV infected individuals was correlated to 
both the number of lifetime oral sex partners as well as the levels of CD4+ cells. It is 
therefore likely, that HPV positivity may primarily be due to persistent or reactivated 
HPV infection in HIV infected individuals, while more recent HPV infections may 
dominate in non-HIV infected individuals.(Beachler et al. 2012) 
 
1.2.5.3 Biological data 
 
There are several molecular/biological differences between HPV positive and HPV 
negative OSCC.(Gillison 2004; Dahlstrand et al. 2005) For example, HPV positive 
TSCCs tend to display fewer chromosomal aberrations as compared to HPV negative 
TSCC (Dahlgren et al. 2003). Moreover, p16INK4a (please see section 1.1.6 and 1.2.7) is 
more frequently overexpressed in HPV positive OSCC compared to HPV negative 
OSCC, while the opposite is documented for e.g. EGFR expression (see section 1.2.6). 
In addition, new high through-put methods have revealed other biological differences 
between HPV positive and negative OSCC, e.g. micro-RNA.(Lajer et al. 2011)  
 
1.2.5.4 Epidemiological data 
 
In addition to biological data (see above, sections 1.1.6 and section 1.2.3), there are also 
strong epidemiology data supporting the role of HPV in a subset of OSCC. Previous 
studies had shown that OSCC patients with HPV positive tumours were younger, 
smoke less, have a better clinical outcome (discussed below).(Lindquist et al. 2007; 
Fakhry et al. 2008; Gillison et al. 2008; Nasman et al. 2009; Attner et al. 2010; 
Dayyani et al. 2010) Although, in addition to the above, many studies have highlighted 
these risk factors, three studies of special interest may be worthwhile to mention. The 
first study from 1999 by Frisch et al showed a 4.3 fold higher risk for developing 
TSCC in patients with HPV associated anogenital cancer, while no corresponding 
increase in any other HNSCC was observed, suggesting the aetiological role HPV in 
TSCC and sexual behaviour as a risk factor.(Frisch et al. 1999) Another interesting 
study from 2000 showed that husbands to women with HPV induced cervical cancer 
had an increased risk of developing TSCC, implying the oncogenic role of and an 
important sexual transmission route for the virus.(Hemminki et al. 2000) A third, more 
recent study from 2008 by Gillison and her group, showed that increased numbers of 
sexual partners (vaginal/oral) was strongly associated with HPV-16 positive HNSCC, 
again supporting oral sex as a risk factor for TSCC.(Gillison et al. 2008) 
 
 
 
1.2.6 HPV and impact of clinical outcome in OSCC  
Today, the evidence for HPV having a favourable prognostic role in OSCC is to be 
considered as strong. There are large randomized control studies published, favouring 
HPV as a positive prognostic marker in OSCC. Examples of such studies are the 
DAHNCA 5 study, where p16INK4a positive (surrogate marker for HPV) OSCC patients 
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presented a better loco-regional control, disease-specific (DFS) and overall survival 
(OS) if treated with conventional radiotherapy.(Lassen et al. 2009) Another such large 
study by Ang et al showed that patients with HPV positive OSCC presented a 
significantly better overall and progression-free survival compared to that of patients 
with HPV negative OSCC, when treated with radio-chemotherapy.(Ang et al. 2010) 
 
There are also numerous retrospective studies indicating a favourable prognostic role of 
HPV in OSCC and the correlation between survival and HPV in HNSCC was recently 
analysed in a meta-analysis by Ragin et al. In this analysis they concluded that patients 
with HPV positive HNSCC in general, and more specifically those with HPV positive 
OSCC, presented a better overall (OS) and disease-free (DFS) survival than those with 
HPV negative malignancies.(Ragin et al. 2007b) Interestingly, in most of the included 
studies in the meta-analysis, there was a discrepancy in prognosis and stage, i.e. tumour 
stage did not influence prognosis in patients with HPV positive OSCC. However, it is 
important to note that there was a huge variation in tumour types (i.e. paraffin 
embedded vs. fresh frozen), HPV detection methods, treatment regimes and outcome 
variables used in the different reports that were included in the meta-analysis. 
Furthermore, in many cases, other tumour sites than OSCC were included in the meta-
analysis. Therefore, although the vast majority of retrospective studies suggest a better 
clinical outcome in patients with HPV positive OSCC, the data compiled in the meta-
analysis should be interpreted with caution.(Ragin et al. 2007b) Nonetheless, one has to 
consider the evidence for a prognostic role of HPV infection in OSCC as strong. 
     
The reason for the positive prognostic role of HPV in HNSCC and OSCC is, however, 
not fully elucidated. Although patient characteristics related to HPV positive OSCC, 
e.g. minimum exposure to alcohol and tobacco, good performance status, young age 
and no comorbidity, all have been liked to a favourable clinical outcome, the studies 
still suggest that HPV by itself is a prognostic factor.(Ang et al. 2010) Furthermore, 
there are retrospective studies that imply that patients with HPV positive OSCC are 
more sensitive to chemotherapy and/or radiotherapy, due to the presence of still 
functional and non-mutated p53.(Pryor et al. 2011) Another mechanism may include 
the, in general, absence of overexpression of EGFR in HPV positive OSCC, which has 
been correlated to radio-resistance in HNSCC in general.(Weinberger et al. 2006; Kong 
et al. 2009; Young et al. 2011) 
 
 
 
1.2.7 HPV and p16INK4a overexpression in OSCC 
As previously described in 1.1.6 and above, p16INK4a is frequently up regulated in HPV 
E7 expressing cells and, thus, p16INK4a has been proposed as a surrogate marker of HPV 
infection in OSCC. Consequently, many studies have linked p16INK4a overexpression to 
presence of HPV DNA in OSCC.(Weinberger et al. 2006; Reimers et al. 2007; Ang et 
al. 2010; Lewis et al. 2010; Thavaraj et al. 2011; Ukpo et al. 2011; Granata et al. 2012; 
Bussu et al. 2013) During the last decade, p16INK4a has gained more and more focus, 
and in 2007 Smeets et al first published an algorithm for HPV detection that included 
p16INK4a.(Smeets et al. 2007; Hoffmann et al. 2010; Rietbergen et al. 2013) 
Unfortunately, this method has gained a lot of attention and has sometimes been 
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regarded as a standard detection method for transcriptional active HPV. In the Smeets 
2007 study, the researchers tested out different HPV detections methods in paraffin 
embedded tumour samples and compared them to - what they defined as the gold 
standard - presence of E6 RNA by RT-PCR in fresh frozen tumours. The researchers 
ended up with presence of p16INK4a followed by GP5+/6+ PCR as the method with 
100% sensitivity and specificity.(Smeets et al. 2007) However, the percentage of 
p16INK4a positive cells varied from 50-90% in the GP5+/6+ PCR positive group. Since 
the authors stated that presence of p16INK4a correlates to transcriptionally active HPV, 
these results raise the question whether HPV was active in only parts of the tumour. 
Another limitation of the study was the limited number of patients. It is also important 
to note, that data describing why HPV DNA may be present in OSCC, without being 
transcriptionally active (e.g. by methylation) are very scarce and were not discussed in 
the Smeets 2007 paper. Subsequently, recent reports have questioned this 
algorithm.(Hoffmann et al. 2012)  
 
Furthermore, the definition of how one should define p16INK4a positivity has changed 
over the years. Initially, different cut-off levels were used, e.g. >10%; 50%; or “diffuse 
and strong intensity”.(Lassen et al. 2011; Granata et al. 2012; Hong et al. 2012) 
However, in 2010, in a randomised controlled study, Ang et al used >70% p16INK4a 
positivity of the tumour cells as a cut-off. Later, the DAHNCA-group, that had 
previously used >10% as cut-off in their prospective studies, showed that only 15/711 
(2%) of their p16INK4a positive OSCC changed p16 status if a cut off of 70% was 
applied instead. Consequently, “to optimise uniformity in prospective reporting of p16-
IHC”, the DAHANCA-group changed their cut-offs to >70% p16INK4a 
positivity.(Lassen et al. 2012) What is important to note however, is that there are no 
biological explanations for using the cut-off described, and one should also always be 
aware of the limitations when using IHC and setting such a precise cut-off (please see 
section 3.2.2.1). Another important point, also observed in our material, is that most 
HPV+ OSCC present with 100% p16INK4a positivity, and with only a minority 
presenting p16INK4a positivity between 10% - <100%. 
 
Nonetheless, the expression of p16INK4a in correlation to clinical outcome, no matter the 
definition of overexpression or the biological mechanisms behind this expression, has 
been studied extensively in OSCC. Almost all published studies have shown a better 
survival in patients with OSCC with p16INK4a overexpression, as compared to those 
with OSCC without p16INK4a overexpression. This survival benefit seems to be 
consistent no matter which survival outcome and treatment modality that has been 
used.(Weinberger et al. 2006; Reimers et al. 2007; Kumar et al. 2008; Lassen et al. 
2009; Ang et al. 2010; Lewis et al. 2010; Rischin et al. 2010; Ukpo et al. 2011; 
Granata et al. 2012) However, very few studies have investigated the prognostic impact 
of p16INK4a overexpression in HPV positive tumours.  
 
 
 
1.2.8 Prognostic biomarkers in OSCC 
Besides p16INK4a and HPV status, many different prognostic markers in OSCC have 
been proposed and the field is hard to overview. Many studies have attempted to 
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investigate standard prognostic markers, such as EGFR overexpression and p53 
mutations. EGFR overexpression that often occurs in HNSCC in general - including 
OSCC - has in many studies been correlated to a worse prognosis, resistance to 
radiotherapy and a poor loco-regional control.(Ang et al. 2002; Burtness et al. 2005; 
Kumar et al. 2008) Likewise, several studies have suggested that HNSCC patients with 
p53 mutations have worse outcomes.(Erber et al. 1998; Licitra et al. 2006; Poeta et al. 
2007) On the other hand, as mentioned above, it has been reported that HPV positive 
OSCC rarely overexpresses EGFR or presents with p53 mutations, as compared to 
HPV negative OSCC.(Westra et al. 2008; Hong et al. 2010)  
 
Nonetheless, there are also plenty other markers e.g. CD8 tumour infiltrating 
lymphocytes and HLA class I expression (both topics of this thesis). Unfortunately, 
however, in the vast majority of biomarker studies in HNSCC, including OSCC, 
researchers have neither taken into account the HPV status of the tumour or specific 
location within HSCC. Recently, newer approaches such as screening for epigenetic 
changes are also emerging in parallel to global scanning methods. Therefore new 
markers are to be expected in HNSCC including OSCC.  
 
Nevertheless, in the search of new prognostic biomarkers, irrespective of the marker, it 
is important to consider the site of the cancer as well as its HPV status. 
 
 
 
1.2.9 Oncological treatment  
The mainstay in HNSCC treatment has for decades been radiotherapy (RT) and/or 
surgery.(Vokes et al. 1993) However, over the last years, treatment has become more 
and more intensified with altered fractionated RT and/or systemic oncological 
therapies. Although the intensification may to some extent have improved survival in 
HNSCC patients in general, this has been to the cost of an increase in early and late 
side effects.(Pryor et al. 2011; Ramqvist et al. 2011a) 
 
In order to improve loco-regional control, different altered fractionated RT regimens 
have been proposed in HNSCC (hyper-fractionated, accelerated and hyper-fractionated 
accelerated RT). While the generally accepted conventional RT fractionation is given 
as 1.8-2 Gy, 5 fractions/week up to a total dose of 66-70 Gy, reduced fractions (1.1-1.2 
Gy) are given 2-3 times daily in hyper-fractionated RT (HRT). In accelerated RT 
(ART), the overall treatment time is reduced by an increase in the amount of doses per 
week and in hyper-fractionated accelerated RT (HART) the two above-mentioned 
strategies are combined. The rationale for ART is to reduce the repopulation of tumour 
cells and thereby improve the effectiveness of the therapy, while the rationale for HRT 
is to increase radiation dose without dramatically increasing side effects.(Zackrisson et 
al. 2003; Bourhis et al. 2006; Duvvuri et al. 2009) 
 
In parallel, different systemic chemotherapy strategies have also been suggested in 
HNSCC, i.e. different cytostatic drugs, different drug combinations and different timing 
for drug administration. Traditionally, a commonly used standard chemotherapy 
regimen in HNSCC has been Cisplatin with/without 5-Flourouracil, although other 
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drugs have been described both in other combinations and as single drugs. 
Furthermore, chemotherapy may be given as “induction chemotherapy” (prior RT or 
surgery); as “concomitant chemotherapy” (synchronous to RT); or as adjuvant 
chemotherapy (after RT or surgery). In addition, EGFR-inhibitors may also be 
administered.(Duvvuri et al. 2009; Pignon et al. 2009)  
 
Consequently, the treatment of HNSCC varies between different clinics and over time, 
which actually to some extent is reflected in paper V of this thesis. Nonetheless, over 
the past decades, researchers have tried to optimize treatment combinations in HNSCC 
patients. 
 
Recently, a meta-analysis was published about altered RT fractionation in HNSCC, in 
which ART and HRT were compared to conventional RT (Bourhis et al. 2006). The 
authors concluded that patients treated with ART without total dose reduction and HRT 
presented a better loco regional control than those treated with conventional RT, but a 
statistical survival benefit was only observed between HNSCC patients with HRT and 
conventional RT. This may suggest that the total radiation dose may be of importance 
for treatment response in HNSCC. 
 
The role of chemotherapy in HNSCC, and in oral and oropharyngeal cancer more 
specifically, has been evaluated in two meta-analyses by Pignon and colleagues from 
2000 and 2009 (Pignon et al. 2000; Pignon et al. 2009); and in one meta-analysis from 
the Cochrane collaboration from 2011(Furness et al. 2011) respectively. No significant 
benefit in survival was observed in patients treated with induction therapy with platin-
based chemotherapy compared to local radiotherapy in any of the studies. Similarly, no 
significant survival benefit was observed if adjuvant chemotherapy was applied. 
However, HNSCC patients treated with concomitant chemotherapy presented a 
significantly better survival than those treated with loco-regional treatment alone. 
(Pignon et al. 2000; Pignon et al. 2009; Furness et al. 2011) 
 
Notably, similar survival benefits of the same order and magnitude were observed, no 
matter whether Cisplatin was used alone, or in combination with 5-Flourouracil, or 
other poly-chemotherapies including either a platin-based drug or 5-Flourouracil. 
However, as mono-chemotherapy, only Cisplatin presented a favourable clinical 
outcome, while other drugs led to inferior results.(Pignon et al. 2000; Pignon et al. 
2009) Interestingly, Pignon and colleagues also compared direct and indirect 
concomitant chemotherapy to induction chemotherapy, and observed a benefit in 
survival for the concomitant treated HNSCC patients.(Pignon et al. 2009) 
 
Although recent studies have focused on optimizing treatment in HNSCC in general, no 
prospective randomized control study has investigated the role of HPV in HNSCC, and 
OSCC more precisely; with regard to the different treatment approaches. As discussed 
previously, numerous studies have evaluated the prognostic role of HPV in OSCC and 
positive HPV status is consistently reported with a favourable DFS, DSS, OS and 
treatment response (section 1.2.6). Hence, the possibility to de-escalate the oncological 
treatment, e.g. RT only, in HPV positive OSCC has been discussed. Although there are 
a few studies up to date (2013-04-12) that are comparing different oncological 
treatments in HPV positive OSCC, there is no currently on-going study assessing 
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chemo-radiation compared to RT alone in HPV positive OSCC.(Chung et al. 2012; 
Mehanna et al. 2012)  
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1.3 UNANSWERED QUESTIONS AT THE TIME WHEN THIS THESIS 
PROJECT WAS INITIATED. 
 
In 2005, when I first joined the research group as a medical student, the group had 
shown that HPV was associated with OSCC, that HPV positive and HPV negative 
OSCC were different entities, and that the former had better clinical outcome of the 
latter. However, IARC had not yet acknowledged HPV as a risk factor for OSCC. 
 
Furthermore, much less was known about the epidemiology of HPV associated OSCC, 
despite that our clinical colleagues had clinically observed an increasing number of 
patients with OSCC.   
 
During the same period in the US, treatment of all HNSCC - including OSCC - was 
being intensified with e.g. chemotherapy and altered fractionated RT regimes. This 
intensification of therapy was also reaching Sweden. 
 
Obviously, with this background it was natural to look more into the epidemiology of 
OSCC and HPV positive OSCC, and this was the aim of the first two papers. 
 
In addition, researchers started to speculate about the possibility to de-escalate the 
intensified treatment of patients with HPV positive OSCC. Nonetheless as described in 
the introduction, additional predictive markers were needed to better single out patients 
with HPV positive OSCC with a very low risk for relapse before de-escalating therapy. 
The aim of the last three papers was to identify useful biomarkers, in an immunological 
context, that could be used in combination with HPV status as a first step to better 
individualise future treatment. 
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2 AIMS 
 
 
• To over time (1970-2007), analyse the HPV prevalence and incidence of 
TSCC and BOTSCC, the two most common sub-sites within OSCC, in 
Stockholm, Sweden.  
(Papers I and II)	  
 
 
• To study the role of CD8+ and Foxp3+ tumour infiltrating cells in TSCC, 
in relation to HPV status and clinical outcome. 
(Paper III)  
 
 
• To investigate the role of “classical” (A, B, C) and “non-classical” HLA 
class I (E and G) in both HPV positive and negative TSCC in correlation 
to clinical outcome. 
(Paper IV) 
 
 
• To extend the previous HLA class I study, and investigate the role 
classical HLA class I as well as HLA class II antigen expression in a large 
cohort of OSCC, in correlation to HPV status and clinical outcome.   
(Paper V) 
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3 MATERIAL AND METHODS 
 
 
3.1 PATIENTS, MATERIALS AND STUDY DESIGNS 
All studies included in this thesis were conducted according to the ethical permissions 
2003/03-386; 2005/431-31/4; 2005/1330-32 and 2009/1278-31/4 from the Regional 
Ethical Committee at Karolinska Institutet, Stockholm, Sweden. Below, the patients 
included in this thesis, and their tumours will be described separately for each paper: 
 
Paper I. All patients with TSCC (ICD-7 145.0) diagnosed between 2003-2007, in the 
Stockholm region, with available pre-treatment paraffin embedded biopsies, were 
included in the study. Patients were identified retrospectively through the local 
Stockholm Cancer Registry, from which the incidence data was obtained as well. The 
diagnoses were verified and patient data were obtained from the medical records. 
Moreover, data obtained (including HPV status) from a previous study by Hammarstedt 
et al (Hammarstedt et al. 2006), on patients with TSCC (also obtained through the 
Stockholm Cancer Registry) diagnosed between 1970-2002 in the Stockholm region, 
were also included here to compare HPV data prevalence/incidence over time. 
 
Paper II. All patients with BOTSCC (ICD-10 C01.9) were identified between 1998 
and 2007, through the Stockholm Cancer Registry, and in total 95 patients with 
available pre-treatment biopsies were included in the study. 
 
Papers III and IV. Patients with TSCC (ICD-10 C09.0-9) diagnosed between 2000-
2006 in the Stockholm region identified through the Swedish Cancer Registry, and with 
available pre-treatment biopsies were included in the study. However, here a “case-
control” approach was applied.  Patients with a poor clinical outcome were the cases 
and those with a favourable clinical outcome constituted controls. More specifically, 
from patients with TSCC biopsies (included in Paper I and Hammarstedt et al 2006), 
we included only those with biopsies that were: (1) HPV DNA and p16INK4a positive or 
(2) HPV DNA and p16INK4a negative. Patients with HPV DNA positive and p16INK4a 
negative of HPV DNA negative and p16INK4a positive tumours were excluded. In 
addition, patients that died of non-TSCC related causes (e.g. hanging) were also 
excluded. The two groups were then divided depending on their 3-year clinical 
outcome (progression-free survival), i.e. not dead of disease and recurrence-free for 3 
years, thus resulting in four groups: 
 
(A) Patients with HPV DNA and p16INK4a positive TSCC and favourable 3-year 
clinical outcome (n=98, in paper IV); a random sample of these (n=31 in 
paper III). 
 
(B) Patients with HPV DNA and p16INK4a positive TSCC and a poor 3-year 
clinical outcome (n=21). 
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(C) Patients with HPV DNA and p16INK4a negative TSCC and a favourable 3-
year clinical outcome (n=11). 
 
(D) Patients with HPV DNA and p16INK4a negative TSCC and a poor 3-year 
clinical outcome (n=20). 
 
In paper V. Here, all patients with OSCC defined by the ICD-10 codes C09.0-9; 
C01.9; C05.1-9; C10.0-9 and diagnosed during a period between 2000-2009 in the 
Stockholm region were included. However, due to technical reasons with the 
Regional Cancer Registry, the inclusion time spans for diagnosis were not 
completely overlapping. More specifically, patients with C09.0-9 and C01.9 were 
diagnosed between January 2000 - September 2009 and patients with C05.1-9 and 
C10.0-9 between January 2000 - January 2009. All patient records were also 
examined and patient characteristics and their clinical outcome were obtained.  
 
 
 
3.1.1 Material considerations 
 
3.1.1.1 The ICD-classification system 
 
As described in the introduction, it is important to note that the classification system 
ICD has changed over time. Therefore, different codes are used in e.g. papers I and 
III, but both papers are analysing TSCC. In paper I the same ICD classification 
system (ICD-7) was used as in Hammarstedt et al (Hammarstedt et al. 2006), since 
it was a continuation of that study, and therefore some TSCC (ICD-10 C09.1 and 
C09.8) were not included in that study. This could have played a role with regard to 
the evaluation of HPV status (see Results and Discussion section 4.1). Nonetheless, 
all patients were identified through the Swedish Cancer Registry, which is regarded 
as almost 100% complete. Therefore, it is highly unlikely that OSCC patients were 
lost in our studies. 
 
3.1.1.2 Study design 
 
A population based retrospective cohort study design was applied in paper I, II and 
V and a case-control study design in paper III and IV. In paper III-V, survival 
measurements were analysed, but in different ways. In papers III-IV, patients with a 
favourable clinical outcome (progression-free survival) were compared to those 
with a poor clinical outcome, and this comparison was made both in patients with 
HPV positive and negative TSCC. In addition, disease-free survival (DFS) was also 
analysed with the Kaplan-Meier method. However, it is important to note that there 
was a selection of patients with regard to clinical outcome in papers III-IV. Besides, 
overall survival was not possible to assess, since patients dying of other causes 
were excluded. Nevertheless, in the following cohort study (paper V), the HLA 
results were verified and here other survival measurements were reported. 
Similarly, in another study from our group, we were able to verify the CD8+ 
results.(Nordfors et al. 2013) 
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3.1.1.3 Biopsies 
 
All biopsies could not be retrieved from all patients diagnosed between the defined 
time spans in the above-mentioned papers and the major reasons for this were, to 
our experience, three: (1) The block was missing at the pathology department. (2) 
Too little tumour material in the biopsy. (3) The diagnosis was made by cytology 
only. The first two reasons were mainly at random and most likely do not affect the 
outcomes of the included papers (I-V). However, it is possible that the third reason 
may have affected the results of papers I and II. Patients diagnosed only by 
cytology are often treated with palliative intent and since there potentially could be 
more patients with HPV negative OSCC in the palliative group, there is a risk that 
we may have a bias in our sample. Nevertheless, it is also very important to note 
that very few patients were diagnosed based on cytology – and this is therefore 
most likely a theoretical rather than a real problem. 
 
3.1.1.4 Treatment modalities. 
 
Treatment modalities were collected from patient records and what gradually came 
apparent, especially in paper V, which is the most recent one, is that treatment 
modalities varied over time. For many years RT and surgery was the treatment of 
choice for OSCC, but (as described in 1.2.9) other treatment approaches have been 
introduced. The Karolinska University Hospital is no exception and the modalities 
have shifted. Thus, in the middle of the last decade, many patients were included in 
the ARTSCAN study, and randomised with regard to accelerated or conventional 
RT.(Zackrisson et al. 2011) Later, many patients were included in a phase II study 
with induction chemotherapy (Cisplatin, 5-Fu and Taxotere), accelerated RT and 
concomitant Erbitux that was followed/not followed by brachytherapy 
(ACCROBAT)(EUCTR2009-013438-26-SE). However, many patients were also 
treated outside these studies. Nevertheless, the reason why the treatment modalities 
differ between paper III-IV and V is mainly due to these studies. In addition, doses, 
schemes and drugs may differ between patients included in papers III-V and for this 
reason only a rough classification of treatment has been made in this thesis.  
 
 
 
3.2 METHODOLOGY 
 
The methods that are used in this thesis are considered as standard procedures in the 
field and are indeed better described in the included papers and elsewhere.(Nasman et 
al. 2009; Attner et al. 2010; Nasman et al. 2012; Nasman et al. 2013) Nevertheless, the 
debate is still on going with regard to which method is the most appropriate for 
detection of HPV. In papers I-V, HPV DNA PCR detection methods have been used. 
Below, this approach and potential limitations will be discussed in more detail. Some 
small comments regarding immunohistochemistry are also included. 
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3.2.1 HPV DNA detection 
 
3.2.1.1 HPV PCR, with general and type specific HPV primers (Papers I-IV) 
 
In papers I-IV, all samples have been tested with the commonly used consensus primer 
pairs GP5+/6+ and CPI/IIG as well as with the type-specific HPV 16 primer pairs (as 
previously described(Nasman et al. 2009)). As explained in the introduction, the 
different consensus primers target different sites of the HPV genome and the HPV 16 
specific primers target the HPV 16 E6 ORF. By combining these primer pairs in an 
algorithm, we should, theoretically, be able to detect HPV genomes with deleted 
sequences in higher frequencies than if only one primer-pair was used.  
 
Figure 10. Algorithm for HPV detection in paper I-IV 
 
 
Nevertheless, a drawback of our algorithm is the typing of HPV. Samples that were 
HPV 16 positive by the type specific primers were considered as only HPV 16, and 
samples that were GP5+/6+ and/or CPI/IIG positive, but HPV 16 negative were 
sequenced to determine the type. Therefore, in theory, in case of a double-infection 
including HPV-16, this would be recorded as an infection with HPV 16 (Figure 10). 
However, this was not the case, since as will be described below, when a Multiplex 
Luminex assay was used instead similar results with dominance of HPV 16 as a single 
infection were obtained. 
 
 
3.2.1.2 S14 PCR for detection of amplifiable human DNA 
 
In papers I-IV, to verify amplifiable human DNA, the S14 primer pairs were used (also 
described elsewhere) in all tumours. The S14 primers amplify a 127bp long sequence 
of the human ribosomal gene S14, which is in size close to that of the amplicons 
generated by the HPV detection primer pairs (GP5+/6+ ~130-150bp; CPI/IIG ~190bp; 
HPV 16 119bp). Consequently, these S14 primer pairs should be more appropriate than 
other housekeeping gene amplicons, which usually are double the size of the GP5+/6+ 
products. Nevertheless, the importance of using a housekeeping amplicon 
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HPV$16$$
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HPV$16$
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approximately the same size as the viral amplicon is based on the assumption that the 
human and viral DNA degrades at the same speed - which we do not know. 
 
 
3.2.1.3 HPV detection by Multiplex Luminex, Paper V 
 
In paper V, all samples were tested with the Multiplex Luminex method, described 
elsewhere(Ramqvist et al. 2011b). This assay is more sensitive, since it uses the 
previously described broad-spectrum GP5+/6+ primers for amplification and it may 
detect up to 24 different types in the typing step. This was partly compensated for using 
a lower amount of DNA in the assay. Moreover, we also validated the method, by re-
analysing samples included in paper I-IV with the Multiplex Luminex method. In view 
of the fact that that the typing of the different types are obtained simultaneously and 
that we detect very few cases of double-infection, suggests that the methods used in 
paper I-IV were adequate. In addition, the human beta-globin gene is used as a 
housekeeping gene. 
 
3.2.1.4 General HPV detection considerations 
 
One of the most important factors that may influence the result of the PCRs is the 
material and its condition. In our studies, we have used formalin fixed, paraffin 
embedded tumour tissues. The advantage using this kind of material is obvious; it is 
easy to get. The disadvantages vary, and include DNA quality and noise from tumour 
stroma and surrounding tissues. Formalin fixation results in DNA bridges, which can 
result in DNA breaks and shorter DNA fragments as compared to what is obtained in 
fresh frozen tumours. Another important factor is that infiltrating lymphocytes and 
surrounding stroma, as well as normal tissues can be present in the biopsies. 
Consequently, when loading the PCRs with the same amount of DNA (100ng in paper 
I-IV and 5-10ng in paper V), the ratio tumour/normal cell DNA may differ. To 
minimize these problems, the tissues were macro-dissected before DNA/RNA was 
extracted.   
 
 
 
3.2.2 Immunohistochemistry 
Immunohistochemistry (IHC) staining protocols are described in more detail in papers 
III-V. Nonetheless, although the staining procedures were similar, different evaluation 
criteria were used for the different antibodies.  
 
 
3.2.2.1 P16 INK4a (papers III-V) 
 
In the case of p16INK4a, which is discussed in the introduction section 1.2.7, two 
different cut-offs were used to define positivity. In paper III-IV, a cut-off of >75% was 
used and in paper V a cut-off of >70% was applied. The reason that we changed cut-off 
in the last paper is, as pointed out in the introduction, that two large prospective trials 
have used the latter cut-off and researchers in the field have started to consider this cut-
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off as “validated”. However, here I would argue that such strict cut-off should be 
questioned for two reasons: (1) There is a lack of a biological reason for the cut-off and 
(2) There is a lack of such precision in the IHC evaluation. Another important general 
point, also applicable for p16INK4a staining, is that staining may vary within the 
tumour and IHC is just a “snap-shot”, looking at only one tiny slice of the tumour. 
 
 
3.2.2.2 HLA staining (papers IV-V) 
 
Different evaluation criteria were used for evaluation of HLA-A, B, C and HLA-E and 
HLA-G respectively, after staining with different specific antibodies for the different 
HLA alleles.  
 
For HLA -A, -B and -C staining, the intensity was evaluated and scored as “absence 
of”, or as “weak” or as “normal” / “strong”. Thus, the intensity was graded similarly in 
paper IV and V, but the nomenclature was changed in the highest intensity staining. 
Fractions of HLA –A, -B and -C positive cells were also evaluated and scored on a 4-
tier scale in paper IV (0%; 1-25%; 26-75% and 76-100%) and on 5-tier scale (0%; 1-
25%; 26-50%; 51-75%; and 76-100%) in paper V. For HLA-E, intensity was scored as 
“absent, “weak”, “medium” and “strong” intensity and grading of fraction of positive 
cells was done according to the 5-tier scale used in paper V for HLA-A, -B and -C 
described above. For HLA-G, only absence of or presence of HLA-G was used. The 
reason for this discrepancy in evaluation was that the different antibodies gave different 
staining patterns and that others had used different scales previously. 
 
Also, worthwhile to comment on, is that HLA intensity could vary within individual 
tumours from weak to strong/normal. Here, the most prominent intensity staining was 
used as intensity score. Consequently, one could argue that intensity staining is 
uncertain. To such statements, I would like to respond that the lowest intensity (absence 
of) is absolute and if intensity staining is correlated to e.g. prognosis, weak intensity 
always presents the intermediate group, flanked by normal/strong and absence of 
staining. 
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4 RESULTS AND DISCUSSION 
 
4.1 INCIDENCE AND PREVALENCE OF HPV IN TSCC AND BOTSCC  
(PAPER I, II AND V) 
In papers I and II, and to some extent in paper V, we wanted to over time, analyse the 
HPV prevalence and incidence of TSCC and BOTSCC, the two most common sub-
sites within OSCC, in Stockholm, Sweden.  
 
In papers I and II, the incidence numbers for the TSCC and BOTSCC were obtained 
from the Swedish Cancer Registry (Figure 11 A and C). The prevalence of HPV DNA 
positive TSCC and BOTSCC was also examined over time (Figure 11 B and D). In 
addition, the TSCC prevalence and incidence data were merged and standardised, in 
order to better present the development over time (Figure 12). In summary, the 
incidence and the HPV DNA prevalence figures has increased significantly over time. 
Below the numbers will be presented in more detail. 
 
 
Figure 11. Incidence and HPV prevalence numbers for TSCC (grey) and BOTSCC (black) respectively. 
(A) Incidence of TSCC (ICD-7 145.0) and (B) prevalence of HPV DNA positive TSCC (ICD-7 145.0) 
over time as well as (C) incidence of BOTSCC (ICD-10 C09.1) and prevalence of HPV DNA positive 
BOTSCC (ICD-10 C09.1) over time.  
 
In paper I, we show that the prevalence of HPV DNA positive TSCC has increased, 
from 23% in the 70´s to 29% in the 1980´s, (p=0.79) to 57% in the 1990´s (p=0.0025) 
and to 79% in 2000-2007 (p<0.0001). This increase was paralleled with an increase in 
TSCC incidence, which increased from 0.74/100,000 person years in the 1970´s to 
1.65/100,000 person years in 2000-2006. In paper II, we showed a similar increase in 
prevalence of HPV DNA positive BOTSCC (from 58% 1998-2001 up to 84% 2006-
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2007, p<0.05) as well as an increased incidence (from 0.15/100,000 person years in 
1970-74 up to 0.47/100,000 person years in 2005-2007). In figure 11 A-D, these data 
are visualised.  
 
Moreover, in paper I, the prevalence data was merged with the incidence data and the 
combination was subsequently standardised to the Swedish population of 1970. Here, 
we were able to show a 7-fold increase in HPV related TSCC, while HPV negative 
TSCC declined. The decrease in HPV negative TSCC is similar to that of lung cancer 
(and other smoking-related tumours in men) with a decrease from the 1980’s. However, 
it is important to note that since we were not able to retrieve all biopsies from all TSCC 
patients, this is an estimate of the incidence of HPV positive and HPV negative TSCC.  
 
Nonetheless, the data in papers I and II strongly suggest that the incidence of HPV 
induced OSCC has increased over time. Therefore, papers I and II together with a 
previous study from our group and a study from Colorado by Ernster et al, were the 
first studies to suggest such an increase.(Hammarstedt et al. 2006; Ernster et al. 2007; 
Nasman et al. 2009; Attner et al. 2010) As discussed in the introduction, other studies 
have followed and confirmed similar developments in other countries 
 
 
Figure 12. Estimated incidence of HPV positive and negative TSCC (ICD-7 145.0) over time. 
 
Furthermore, as discussed previously in the introduction and in the material and 
methods section, the numbers obtained for TSCC and BOTSCC in papers I and II 
should be compared with caution, since different classification systems and time spans 
were used. Notably, in paper V (Table 1) all patients were classified by the same 
system and obtained at the same time. In this table, all patients diagnosed between 
2000-2009 with available pre-treatment biopsies and treated with the intention to cure 
were included. Although it is not clearly stated in paper V, 77% of the TSCC (C09.0-9) 
and 73% of the BOTSCC (C01.9) biopsies were HPV positive between 2000-2009. 
The reason between the discrepancies between papers I and II on the one hand and 
paper V on the other hand is that a lower HPV prevalence was observed for the ICD-10 
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codes C05.1-9 and C10.0-9 used in paper V. The HPV prevalence development over 
time in the different ICD-10 diagnoses used in paper V is presented in figure 13.  
 
In this figure, it becomes apparent that, although TSCC dominates in total numbers, the 
HPV prevalence is similar in TSCC and BOTSCC. Another observation is that the 
increased prevalence in TSCC is less obvious if the ICD-10.0-9 classification is used 
instead of ICD-7 145.0. However, the difference in HPV prevalence between 2000-
2002 and 2006-2008 in ICD-10 09 OSCC is still significant (p<0.05) (Figure 13). 
 
 
 
Figure 13. HPV prevalence in different sites of OSCC between 2000-2008 (data not published).  
 
There is a remarkable difference in HPV prevalence within the different ICD-10 C09 
codes. While the C09.0 (tonsils) has an HPV prevalence of 79% during 2000-2009, it is 
only 14% for C09.1 (tonsillar pillars). Moreover, during the same time span, C09.8 
(large TSCC) and C09.9 (unspecified TSCC) had a prevalence of 63% and 57% 
respectively (data not published). Therefore, when stated in this thesis that soon almost 
all TSCC will be HPV positive, this should be interpreted in the context of ICD-7 145.0 
and not ICD-10 C09.0-9. 
 
Nevertheless, in both TSCC and BOTSCC >90% of the HPV positive cases, were 
accounted for by HPV16, which dominated completely, and in these cases E6 and/or 
E7 was present in the vast majority of cases (again > 90%). Furthermore, patients with 
HPV DNA positive TSCC and BOTSCC were often younger (papers I, II and V) and 
were non-smokers to a higher extent (paper V). They also had smaller tumours (papers 
I, II and V); but tended to have higher tumour stages (significant in paper II and V, but 
not in I) and tended to have less differentiated tumours (significant in paper I, but not in 
II and V).  
  
Conclusion. The incidence of TSCC and BOTSCC has increased and this increase has 
been paralleled by an increase in HPV prevalence, suggesting that HPV infection is 
responsible for this rise in TSCC and BOTSCC. 
 
0%#
20%#
40%#
60%#
80%#
100%#
2000)2002# 2003)2005# 2006)2008#
C09.0%9&
C01.9&
C05.1%9&
C10.0%9&
  47 
4.2 TUMOUR INFILTRATING LYMPHOCYTES AND HPV STATUS IN 
CORRELATION TO CLINICAL OUTCOME. 
(PAPER III)  
In Paper III the aim was to study the role of CD8+ and Foxp3+ tumour infiltrating cells 
in TSCC, in relation to HPV status and clinical outcome.  
 
In summary, a high CD8+ count as well as a high CD8+/Foxp3 ratio correlated to a 
favourable clinical outcome in both HPV positive and negative TSCC. In addition, 
HPV positive TSCC presented significant higher levels of TILs. Below the data is 
presented in more detail. 
 
Patients with HPV positive TSCC with a favourable clinical outcome, defined here as 
progression free survival (see 3.1.2), had a higher mean CD8+ TIL count compared to 
those with a poor clinical outcome (61.4 vs. 19.4, p<0.01). Similarly had a higher mean 
CD8+ TIL count compared to those with a poor clinical outcome (61.4 vs. 19.4, 
p<0.01). Similarly, patients with HPV negative TSCC with a good clinical outcome 
had a higher mean CD8+ TIL count than those with a poor clinical outcome (19.4 vs. 
4.7, p=0.001)(Figure 14A). However, when patients with HPV positive and negative 
TSCC with good and poor clinical outcome were compared with regard to numbers of 
Foxp3+ TILs, no differences were observed (HPV positive TSCC: 33.7 vs. 32.5, p=0.9; 
HPV negative TSCC: 11.7 vs. 16.4, p=0.6) (Figure 14B). When CD8/Foxp3 ratios were 
evaluated however, both patients with HPV positive and HPV negative TSCC with a 
good clinical outcome tended to have higher ratios than those with a poor clinical 
outcome (HPV positive TSCC: 3.0 vs. 1.5, p=0.09 and HPV negative TSCC: 8.2 vs. 
1.1, p=0.10) (Figure 14 C).  
 
 
Figure 14. CD8+, Foxp3+ and CD8+/Foxp3+ ratio 
in correlation to HPV status and clinical outcome 
(good/poor) in TSCC.  
 
(A) Mean CD8+ TILs levels in correlation to HPV 
status and clinical outcome; HPV status only; and 
clinical outcome only. A high CD8+ TIL mean 
count correlated to favourable outcome in patients 
with HPV positive and negative TSCC (p<0.01 and 
p<0.001 respectively); to HPV status in TSCC 
(p<0.001); and to outcome in general (p<0.001).    
 
(B) Mean levels of Foxp3+ TILs in correlation to 
HPV status and clinical outcome; HPV status only; 
and clinical outcome only. A high Foxp3 TIL mean 
was associated with positive HPV status (p<0.001). 
 
(C) Mean CD8+/Foxp3 ratio in correlation to HPV 
status and clinical outcome; HPV status only; and 
clinical outcome only. No significant differences 
were observed, but there was a trend a higher ratio to 
be correlated to a better outcome.  
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Additionally, HPV positive TSCC, as compared to HPV negative TSCC, had 
significantly higher mean levels of CD8+ TILs (45.6 vs. 9.9, p<0.001) and significantly 
higher mean levels of Foxp3 TILs (33.2 vs.14.7, p<0.001). However, no significant 
differences in CD8+/Foxp3+ ratios were observed (Figure 14 A-C).  
 
A Kaplan-Meier analysis on disease-free survival (DFS) was also performed for 
patients with HPV positive and negative TSCC. Here, patients with HPV positive 
TSCC were divided into two groups based on median CD8+ TIL count. Patients with a 
high CD8+ TIL count had a significant better DFS than those with a count under the 
group median (log-rank test: 0.02). Similarly, patients with HPV negative TSCC with a 
high CD8+ TIL count had a better DFS than those with tumours with a low CD8+ TIL 
count, but here the differences did not reach significance (log-rank 0.17). If, however, 
the CD8+/Foxp3+ ratio was assessed, a high ratio (above 1) in HPV positive as well as 
in HPV negative TSCC was correlated to a better DFS (p=0.04 and p=0.03 
respectively).   
 
Moreover, in a Cox proportional univariable and multivariable analysis (adjusting for 
age, sex and stage) numbers of CD8+ TILs were used in patients with HPV positive 
TSCC, and the CD8+/Foxp3+ ratio was used in patients for HPV negative TSCC. In 
the HPV positive group, a high CD8+ TIL count was correlated to a favourable DFS 
both in the univariable and the multivariable analysis (HR 0.27, 95% CI 0.09-0.88 and 
HR 0.28, 95% CI 0.084-0.91 respectively). Likewise, in the HPV negative group, a 
CD8+/Foxp3+ ratio above 1.0 correlated with a favourable DFS, both in the univariable 
and the multivariable analysis (HR 0.27, 95% CI 0.073-0.99 and HR 0.21, 95% CI 
0.057-0.81 respectively).  
 
In summary, the results regarding TILs and clinical outcome are in concordance with 
previous published studies in HNSCC (Ogino et al. 2006) and other malignancies, e.g. 
cervical cancer.(Nedergaard et al. 2007; Piersma et al. 2007). In this study, we were 
also able to show the significance of HPV status and, as an indication of how important 
it is to separate HNSCC according to HPV when e.g. searching for new prognostic 
markers. 
 
Finally, the expression of the cyclooxygenase-2 (Cox-2) enzyme was also examined in 
relation to infiltrating Foxp3+ cells. The rationale was that, Cox-2 has been suggested 
to indirectly induce up-regulation of Foxp3 expression, which is necessary for Treg 
function.(Baratelli et al. 2005; Sharma et al. 2005) However, no significant correlations 
between Foxp3 and Cox-2 were observed. Furthermore, in contrast to previously 
published papers in OSCC, Cox-2 expression did not by itself correlate to clinical 
outcome in either HPV positive or negative TSCC.(Chang et al. 2004) However, HPV 
positive tumours tended to have a stronger Cox-2 expression by intensity than HPV 
negative tumours (73% vs. 52%), and the difference was significant when adjusted for 
prognosis (p=0.049). 
 
Conclusion. Patients with HPV positive and negative TSCC with a high numbers of 
CD8+TILs have a better clinical outcome than those with tumours with low numbers of 
CD8+ TIL, indicating the number of CD8+ TILs could potentially be used a prognostic 
marker in TSCC– but this should first be validated in a prospective trial.   
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4.3 EXPRESSION OF HLA CLASS I (-A, -B -C, -E AND -G) IN TSCC AND 
ITS CORRELATION TO CLINICAL OUTCOME. 
(PAPER IV) 
In paper IV, the aim was to investigate the role of “classical” (A, B, C) and “non-
classical” HLA class I (E and G) in both HPV positive and negative TSCC in 
correlation to clinical outcome. 
 
In summary, absence of/weak HLA –A, B and C expression was correlated with a 
favourable clinical outcome in patients with HPV positive TSCC, and to a worse 
clinical outcome in patients with HPV negative TSCC. No outcome correlations were 
observed for HLA-E and -G. The data are presented in more detail below. 
 
Patients with HPV positive TSCC with absence of/weak HLA class I intensity 
presented a very favourable clinical outcome significantly more often than those with 
high HLA intensity (Table 4). Similar results were obtained if absence/presence of or 
localisation of HLA class I staining was evaluated (Table 4). However, no correlation 
between clinical outcome and HLA-E or HLA-G expression could be observed. 
 
Table 4. HLA class I expression in HPV positive TSCC with good vs. poor clinical outcome.  
 
Good 
clinical 
outcome†
Poor   
clinical 
outcome†
N (%) N (%)
Absent / Weak 77 (79) 8 (38) 1
Normal 21 (21) 13 (62) 5.9 (2.0 to 19)
Absent / Weak 68 (69) 8 (38) 1
Normal 30 (31) 13 (62) 3.6 (1.3 to 11)
Absent 34 (35) 2 (10) 1
Present‡ 64 (65) 19 (90) 5.0 (1.1 to 47)
Absent 25 (26) 1 (5) 1
Present‡ 73 (74) 20 (95) 6.8 (1.0 to 295)
Absent 34 (35) 2 (10) 1
Cytoplasmatic 48 (49) 8 (38) 2.8 (0.6 to 14.1)
Membranous 16 (16) 11 (52) 11.7 (2.3 to 59)
Absent 25 (27) 1 (5) 1
Cytoplasmatic 46 (47) 11 (52) 6.0 (0.7 to 49)
Membranous 27 (28) 9 (43) 8.3 (1.0 to 70.6)
Absent / Weak 59 (60) 16 (76) 1
Moderate /Strong 39 (40) 5 (24) 0.5 (0.1 to 1.6)
Absent 17 (17) 3 (15) 1
Present‡ 81 (83) 18 (85) 1.6 (0.3 to 16)
Absent 90 (92) 17 (81) 1
Present 8 (8) 4 (19) 2.6 (0.5 to 11)
* HPV status obtained from previous studies
†† Odds ratio of poor clinical outcome estimated using exact logisitc regression
‡ Present referes to staining score 1-3
§ Antibodies binding to classical HLA class I (A, B and C) heavy chain. 
p=0.001
p=0.09
p=0.22
p=1.0
† Clinical outcome defined as recurrence free and alive 3 year after diagnosis (good) and as dead of disease or recurrence within 3 years after treatment (poor).
p=0.22
Factor
HLA-E 
intensity
HLA-E 
presence
HLA-G 
presence
HCA-2§ 
intensity
HC-10§ 
intensity
HCA-2§ 
presence
HC-10§ 
presence
HCA-2§ 
localization
HC-10§ 
localization
p=0.042
p-value
p<0.001
p=0.011
p=0.034
Odds ratio (95% CI)††
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Conversely, in patients with HPV negative TSCC a higher intensity staining and 
presence of HLA class I expression as compared to weak intensity staining and absence 
of expression was correlated to a favourable clinical outcome. Expression of HLA-E 
and HLA-G did not correlate to outcome (Table 5). 
 
Table 5. HLA class I expression in HPV positive TSCC with good vs. poor clinical outcome. 
 
 
A Kaplan-Meier analysis on disease-free survival (DFS) was performed, both for 
patients with HPV positive and negative TSCC. In the HPV positive group, 100% of 
the patients with absence of HLA class I (HCA-2) remained disease-free 3 years after 
diagnosis, while this was the case for 90% of those with a weak, and for only 69% of 
the patients with normal intensity staining (log-rank test p<0.001). Similar results were 
obtained with the HC-10 mAb, with 100% of the patients with absence of HLA class I 
remaining disease-free 3 years after diagnosis, while this was the case for 90% of those 
with a weak, and for only 76% of the patients with normal intensity staining (log-rank 
test p=0.01).  
 
In patients with HPV negative TSCC, a normal HCA-2 intensity was associated with a 
better 3-year DFS and 67% of the patients remained disease-free, while 40% of the 
weak intensity and none of the those with absence of HLA class I intensity staining 
remained disease free (log-rank test p<0.022). If HC-10 mAb was used instead, normal 
Good 
clinical 
outcome†
Poor   
clinical 
outcome†
N (%) N (%)
Absent / Weak 1 (9) 14 (70) 1
Normal 10 (91) 6 (30) 0.05 (0.001 to 0.46)
Absent / Weak 1 (9) 12 (60) 1
Normal 10 (91) 8 (40) 0.1 (0.001 to 0.7)
Absent 0 (0) 8 (40)
Present‡ 11 (100) 12 (60) -
Absent 0 (0) 5 (25)
Present‡ 11 (100) 15 (75) -
Absent 0 (0) 8 (40)
Cytoplasmatic 0 (0) 7 (35) -
Membranous 11 (100) 5 (25)
Absent 0 (0) 8 40)
Cytoplasmatic 0 (0) 7 (35) -
Membranous 11 (100) 5 (25)
Absent / Weak 6 (55) 10 (50) 1
Moderate /Strong 5 (45) 10 (50) 1.2 (0.2 to 6.8)
Absent 0 (0) 1 (5)
Present‡ 11 (100) 19 (95) -
Absent 10 (91) 20 (100)
Present 1 (9) 0 (0) -
* HPV status obtained from previous studies
†† Odds ratio of poor clinical outcome estimated using exact logisitc regression
‡ Present referes to staining score 1-3
§ Antibodies binding to classical HLA class I (A, B and C) heavy chain. 
p<0.001
p=1.0
p=0.002HCA-2
§ 
intensity
HC-10§ 
intensity
HCA-2§ 
presence
p=1.0
p=0.36
p=0.008
p=0.028
p=0.13
p<0.001
† Clinical outcome defined as recurrence free and alive 3 year after diagnosis (good) and as dead of disease or recurrence within 3 years after treatment (poor).
p-valueOdds ratio (95% CI)††Factor
HCA-2§ 
localization
HC-10§ 
localization
HLA-G 
presence
HLA-E 
presence
HC-10§ 
presence
HLA-E 
intensity
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intensity staining presented the best DFS (63% disease-free) followed by weak (33%) 
and absence of HLA class I intensity staining (0%)(log-rank test p=0.05). 
 
Furthermore, when HCA-2 staining intensity (absence of/weak vs. strong) was used in 
a univariable Cox-regression model, we found that patients with HPV positive TSCC 
with normal intensity were 6.1 times more likely to have a recurrence in disease than 
those with absence of/weak HCA-2 staining intensity (HR 6.1, 95% CI 2.1-18.0, 
p=0.001). Conversely, patients with HPV negative TSCC with a normal HCA-2 
intensity staining had a 5-fold decreased risk of relapse (HR 0.23, 95% CI 0.07-0.73, 
p=0.013). When HCA-2 intensity staining was adjusted for stage, age and sex in a 
multivariable analysis, absence of/weak staining was still correlated to a favourable 
DFS in the HPV positive group (HR 6.6, 95% CI 2.2-19.7, p=0.001), and to a worse 
DFS in the HPV negative group (HR 0.14, 95% CI 0.02-0.92, p=0.04). Similar results 
were obtained if HC-10 staining intensity was used instead, both in the univariable 
analysis (HPV positive TSCC: HR 3.9, 95% CI 1.3-11.5, p=0.012 and HPV negative 
TSCC: HR 0.27, 0.09-0.83, p=0.022) and the multivariable analysis (HPV positive 
TSCC: HR 4.1, 95% CI 1.4-12.2, p=0.011 and HPV negative TSCC: HR 0.31, 95% CI 
0.08-1.2, p=0.09).   
 
The fact that absent/weak MHC expression correlated with a very good prognosis in 
HPV positive OSCC was an unexpected finding. However, in e.g. breast cancer, a 
complete loss of MHC class I together with a favourable prognosis has been suggested 
to be due to NK-cell activity and an association between loss of MHC and resistance to 
apoptosis. Therefore, eradication of HLA lacking tumours by NK-cells could be an 
explanation of the favourable prognosis in these TSCC tumours. We therefore also 
assessed tumour infiltrative NK-cells (CD56 positive cells by IHC). The numbers of 
NK cells were low and no correlations to lack of HLA class I, HLA-G or to clinical 
outcome were observed (data not published). 
 
Conclusion. In summary, absence of and weak HLA-A, -B and -C intensity was 
associated with a favourable clinical outcome in patients with HPV positive TSCC, but 
with a worse in patients with HPV negative TSCC. These finings will be further 
discussed below in Paper V. 
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4.4 EXPRESSION OF CLASSICAL HLA CLASS I AND HLA CLASS II IN 
OSCC AND ITS RELATION TO SURVIVAL 
(PAPER V) 
In paper V, the aim was to extend the previous HLA class I study in paper IV, and 
investigate the role classical HLA class I as well as HLA class II antigen expression in 
a large cohort of OSCC, in correlation to HPV status and clinical outcome.   
 
In summary, absence of HLA –A, B and C expression in patients with HPV positive 
OSCC correlated to a very high disease-free survival (DFS), disease-specific survival 
(DSS) and overall survival (OS), independent of treatment regime. The opposite was 
observed in patients with HPV negative OSCC. HLA class II expression was correlated 
to a better prognosis in patients with HPV negative, but not in patients with HPV 
positive OSCC. The data is presented in more detail below: 
 
In total, 551 OSCC patients were obtained from the Swedish Cancer Registry and 484 
out of these were oncologically treated with the intention to cure. In total, 45 of the 
treated patients had no pre-treatment biopsies available. However, there were no 
differences between the 439 patients with biopsies and the 45 without biopsies with 
regard to patient characteristics, except for treatment – where patients with missing 
blocks were more likely to receive only RT as compared to patients with available 
blocks (p=0.007).  
 
In total, 303/439 (69%) of the tumours were HPV positive and patients with HPV 
positive OSCC had a better DFS, DSS and OS as compared to those with HPV 
negative tumours, both in the univariable and multivariable analysis (adjusted for age, 
sex stage and tumour localisation) (Table 6).  
 
Table 6. HPV status and survival 
 
 
Moreover, when classical HLA class I and HLA class II expression was analysed in 
HPV positive and negative OSCC there were significant differences. HLA class I 
expression was more often down-regulated and HLA class II expression was more 
often up-regulated in HPV positive OSCC, as compared to HPV negative OSCC (Table 
7).  
 
 
 
Univariable analysis Multivaraible analysis*
HR (95% CI) HR (95% CI)
HPV negative (N=136) 1  (ref) 1  (ref)
HPV positive (N=303) 0.30 (95% CI 0.19-0.48) 0.30 (95% CI 0.18-0.50)
HPV negative (N=136) 1  (ref) 1  (ref)
HPV positive (N=303) 0.23 (95% CI 0.15-0.36) 0.23 (95% CI 0.15-0.36) 
HPV negative (N=136) 1  (ref) 1  (ref)
HPV positive (N=303) 0.26 (95% CI 0.18-0.37) 0.27 (95% CI 0.18-0.39)
DFS
DSS
OS
* adjuseted for age, sex, stage and tumour localisation
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Table 7. Classical HLA class I and HLA class II staining in relation to HPV status 
 
 
Subsequently, the cohort was divided into a HPV positive and a HPV negative OSCC 
cohort and HLA expression was analysed in correlation to survival. In patients with 
HPV positive OSCC, absence of classical HLA class I expression was associated with a 
very high survival, while a strong intensity of the same was associated with a worse 
(Figure 15). 
 
 
Figure 15. Kaplan-Meier curves for DFS, DSS and OS in patients with HPV positive OSCC. (A) DFS 
stratified for HCA-2 intensity, (B) DSS stratified for HCA-2 intensity, (C) OS stratified for HCA-2 
intensity, (D) DFS stratified for HC-10 intensity, (E) DSS stratified for HC-10 intensity, and (F) OS 
stratified for HC-10 intensity. 
 
Patients with HPV positive OSCC and absence of HLA class I intensity had a significantly better survival 
than those with a strong HLA class I intensity staining, while weak intensity staining presented an 
N % N % p-value§
absent 101 33% 24 18%
weak 60 20% 45 33%
strong 142 47% 67 49%
absent 101 33% 24 18%
1-25% 33 11% 14 10%
26-50% 24 8% 16 12%
51-75% 33 11% 14 10%
76-100% 112 37% 68 50%
absent 60 20% 9 7%
weak 73 24% 33 24%
strong 170 56% 94 69%
absent 60 20% 9 7%
1-25% 24 8% 7 5%
26-50% 16 5% 4 3%
51-75% 39 13% 15 11%
76-100% 164 54% 101 74%
absent 100 55% 82 45%
weak 29 73% 11 28%
strong 174 80% 43 20%
absent 100 55% 82 45%
1-25% 26 72% 10 28%
26-50% 23 77% 7 23%
51-75% 34 74% 12 26%
76-100% 120 83% 25 17%
§"Chi&square"test
Positive
HPV status
Intensity of     
HCA-2      
positive cells
Fraction of      
HCA-2         
positive cells
Negative
0.001
0.009
0.001
0.001
Intensity of     
LGII-612.14 
positive cells
Fraction of       
LGII-612.14 
positive cells
<0.001
<0.001
Intensity of      
HC-10     
positive cells
Fraction of      
HC-10    
positive cells
Figure'1'
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intermediate survival (HCA-2: DFS p<0.001; DSS p=0.060; OS p=0.022; HC-10: DFS p=0.003, DSS 
p=0.021 and OS p=0.009).  
The survival data was also analysed in a univariable and a multivariable model, 
adjusted for age, sex, stage and tumour site. Patients with HPV positive OSCC and 
absence of classical HLA class I staining still presented a better DFS, DSS and OS in 
the univariable (HCA-2: p=0.0019, p=0.062 and p=0.016 respectively and HC-10: all 
disease-free, p=0.025 and p=0.011 respectively) and in the multivariable (HCA-2: 
p=0.003, p=0.11 and p=0.033 respectively and HC-10: all disease-free, p=0.040 and 
p=0.024 respectively). Although the differences did not reach significant levels in the 
DSS analysis with the HCA-2 mAb, the trend was still similar to what was observed in 
the other survival measurements. Additionally, HLA class II was also analysed in 
correlation to survival, but here no survival associations were observed. 
 
Consequently, the results in paper V showing that absent/weak HLA class I intensity 
staining in HPV positive OSCC was a prognostic favourable factor, was in line with 
and confirmed our previous findings in in paper IV for HPV positive TSCC. 
Nevertheless, the reason for the association between lack of HLA class I and a 
favourable survival is still unravelled. The down-regulation of HLA class I could, as 
described in the introduction, indeed be due to the repression of HLA by E7 or E5 and 
that the favourable prognosis is due to viral activity. Another explanation may be that 
the viral repression of HLA is overpowered by a possible increase in HLA class I 
expression after RT. Interestingly, previous studies have actually shown an up-
regulation of HLA class I expression after RT in cervical cancer and also in myeloma 
cell lines.(Mikyskova et al. 2005; Chiriva-Internati et al. 2006) Similar results were 
also obtained in breast cancer, and here the authors concluded that the up-regulation 
was due to an increased peptide pool.(Reits et al. 2006) On the other hand, a study 
some years ago suggested that down-regulated HLA class I expression can be due to 
viral integration within the HLA foci.(Sheu et al. 2005) Such suggestions contradict the 
previous line of thoughts. Other explanations may include differences in the immune 
defence against HPV, and thus an immune selection, or due to NK-cell activity, which 
however is less likely here as discussed in paper IV. 
 
Nonetheless, in the HPV negative OSCC cohort, the opposite results were obtained. In 
general, patients with HPV negative OSCC with a strong classical HLA class I 
expression presented a better survival than those with absence of or weak intensity 
staining. In addition, a strong HLA class II expression was in general associated with a 
better DFS, DSS and OS, both in the univariable and the multivariable analysis. 
Notably, similar results obtained in patients with HPV negative OSCC have previously 
been reported in other malignancies and highlight the atypical and very different nature 
of HPV positive OSCC compared to HPV negative OSCC. 
 
Furthermore, oncological treatment (RT vs. CRT) was also examined in relation to 
HLA class I expression in patients with HPV positive OSCC. Interestingly, no 
differences in DFS, DSS and OS were observed between RT and CRT in patients with 
HPV positive OSCC with absence of or with weak HLA class I expression. More 
specifically, no differences were observed in the patients with absence of HLA class I 
expression with regard to DFS, DSS and OS (HCA-2: p=0.91, p=0.94 and p= 0.68 
respectively; and HC-10: p=1.00, p=0.46 and p=0.20 respectively). Analogously, no 
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differences were observed in the patients with HPV positive OSCC with weak HLA 
class I intensity with regard to DFS, DSS and OS (HCA-2: p=0.15, p=0.88 and p=1.0 
respectively; and HC-10: p=0.27, p=0.82 and p=0.99 respectively). In contrast to the 
other two groups, patients with HPV positive OSCC with a strong HLA class I staining 
intensity had a significantly better DFS, DSS and OS if treated with CRT than with RT 
(presented for DSS in Figure 16). 
 
Figure 16. Kaplan-Meier curves for DSS in patients with HPV positive OSCC and different treatment 
regimes. (A) DSS in HPV positive OSCC with absent HCA-2 intensity stratified RT and CRT, (B) DSS 
in HPV positive OSCC with weak HCA-2 intensity stratified RT and CRT, (C) DSS in HPV positive 
OSCC with strong HCA-2 intensity stratified for RT and CRT, (D) DSS in HPV positive OSCC with 
absent HC-10 intensity stratified for RT and CRT, (E) DSS in HPV positive OSCC with weak HC-10 
intensity stratified for RT and CRT, (F) DSS in HPV positive OSCC with strong HC-10 intensity 
stratified for RT and CRT. 
 
It is important to note however, that there was most probably a selection bias for more 
patients with a poor clinical status receiving only RT than CRT, which probably 
explains the differences in the strong HLA class I intensity staining group. 
Nevertheless, irrespective of treatment with CRT or RT and a possible bias in selection 
of treatment, patients with HPV positive OSCC with an absence of, or weak HLA class 
I expression presented very high DFS, DSS and OS. In other words, even if patients 
with poorer health conditions were over-represented in the RT groups, still there were 
no differences in any survival measurements in the absence of and the weak intensity 
staining groups. Therefore, since patients with HPV positive OSCC with absence of 
HLA class I present with a very high survival, independent of treatment regime, these 
patients could potentially be the first to be randomized into a prospective experimental 
study for de-escalation of oncological treatment. 
 
Conclusion. Patients with HPV positive OSCC with absence of/weak HLA class I 
intensity staining have a better DFS, DSS and OS, independent of treatment regime, 
than those with HPV positive OSCC and strong HLA class I intensity staining. 
Furthermore, patients with HPV negative OSCC and a strong HLA class I and/or HLA 
class II expression have a better survival than those with HPV negative OSCC and 
absence of HLA class I and/or class II expression. Finally, HPV positive OSCC 
Figure'2'
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generally expresses lower levels of HLA class I and higher levels of HLA class II 
antigens than HPV negative OSCC.   
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5 CONCLUSIONS 
 
 
 -­‐ The incidence of TSCC and BOTSCC has increased and this increase has 
been paralleled by an increase in HPV prevalence, suggesting that HPV 
infection is responsible for this rise in TSCC and BOTSCC.  
(Papers I and II) 
 -­‐ Patients with HPV positive and negative TSCC with high numbers of CD8+ 
TILs have a better clinical outcome than those with low numbers of CD8+ 
TILs. (Paper III)  
 -­‐ HPV positive TSCC had in general higher numbers of CD8+ and Foxp3+ 
TILs as compared to HPV negative TSCC. (Paper III) 
 -­‐ Patients with HPV positive OSCC with absence of/low HLA class I intensity 
staining had a very high DFS, DSS and OS independent of treatment regime, 
and compared to those with HPV positive OSCC and a strong HLA class I 
intensity staining. (Papers IV and V). 
 -­‐ HPV positive OSCC generally expresses lower levels of HLA class I and 
higher levels of HLA class II antigens than HPV negative OSCC.  
(Papers IV and V). 
 -­‐ Patients with HPV negative OSCC with a strong HLA class I and/or HLA 
class II expression have a better survival than those with HPV negative OSCC 
with absence of HLA class I and/or class II expression.  
(Papers IV and V). 
 -­‐ Finally, we could confirm that patients with HPV positive OSCC have a better 
disease-free (DFS), disease-specific (DSS) and overall survival (OS) than 
patients with HPV negative OSCC. (Paper V) 
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6 FUTURE PERSPECTIVES 
In papers I and II we demonstrated an increase in HPV positive TSCC and BOTSCC. 
Whether or not this trend will continue to increase in OSCC is not easy to predict, since 
smoking and alcohol (the other risk factors for OSCC) are still present in the Stockholm 
population. From the slope of the incidence and prevalence curves we have 
demonstrated in this thesis we may probably have reached the top of HPV prevalence 
in OSCC in Stockholm. However, this is still not certain. Furthermore, with a new era 
with public HPV vaccination of young women, and a possible heard immunity in 
males, it would, still be interesting to follow possible changes in the prevalence of HPV 
in general and in the prevalence of different HPV types in OSCC in the future.  
 
In papers III-V we identified two potentially interesting immunological predictive 
markers (CD8+ TIL counts and HLA class I intensity staining) for clinical outcome. 
Our results were however obtained from observational retrospective studies where 
treatment was not randomised and this presents a limitation of our studies, although 
there are good reasons to assume that the results are valid. Besides, as discussed in the 
introduction, it is still uncertain how much the different treatment modalities influence 
survival. Nevertheless, a prospective randomised study should be conducted in patients 
with HPV positive OSCC with absence of HLA class I expression, or with high CD8 
levels, or using a combination of both these markers, in which patients were 
randomised into controls (receiving CRT) and into cases (receiving RT only). 
 
Lastly, the mechanisms behind the down-regulated HLA class I and the correlation to a 
favourable clinical outcome should be further studied. Is it due to a viral repression of 
intact HLA class machinery that is up-regulated upon treatment and overrides the viral 
repression? Or is it due to something completely else? Answers here may be useful in 
conducting future therapies. 
 
As always, answers lead to new questions and challenges. 
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